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 Oxidative stress occurs when there is an overproduction of reactive nitrogen and oxygen 
species in the body. This condition has been linked to many prominent diseases. This thesis details 
analytical methods that use fluorescence derivatization in order to detect small molecule 
biomarkers of oxidative stress as they relate to epilepsy, inflammation, and traumatic brain injury. 
 A liquid chromatography-fluorescence method was developed for the detection of reactive 
aldehyde biomarkers, which are by-products of oxidative stress following epileptic seizures. The 
method was applied to an animal model of epilepsy and used to monitor concentrations of the 
analytes over several days in urine samples. This study revealed a circadian cycling of these 
aldehydes, as well as elucidating which ones were present at increased levels after a seizure. 
 A microchip electrophoresis-fluorescence method was then developed for the detection of 
carnosine, an endogenous dipeptide that is involved in oxidative stress-induced inflammation 
following prolonged activation of macrophage cells. The method was used to measure the native 
presence of carnosine in these cells, as well as investigate its uptake under normal and pro-
oxidative conditions. This study indicated that carnosine’s antioxidant properties might lead to its 
increased uptake by macrophage cells under inflammatory conditions. 
 Another microchip electrophoresis-fluorescence method was developed to examine 
excitatory amino acid neurotransmitters involved in neuronal damage following traumatic brain 
injury. The microchip electrophoresis chip was coupled to microdialysis sampling with on-line 
derivatization for continuous monitoring of these analytes with a total lag time of twelve minutes 
and 90 second temporal resolution. Further work with this system will focus on improving the 
limits of detection so that it could be used by medical professionals to monitor the neurochemical 
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Analytical Techniques for Monitoring Biomarkers of Oxidative Stress 
1.1.  Research Objectives 
Oxidative stress is a state where the excessive production of reactive nitrogen and oxygen 
species (RNOS) overcomes the body’s natural antioxidant defense system, resulting in damage to 
biomolecules and the alteration of biochemical pathways [1]. Oxidative stress has been linked to 
several prominent disease states such as Alzheimer’s disease [2], Parkinson’s disease [3], ischemia 
[4], diabetes [5], cancer [6], inflammation [7], traumatic brain injury [8], and epilepsy [9]. 
Oxidative stress has even been proposed as a key component of the free radical theory of aging, in 
which the decline of the antioxidant defense system is responsible for aging [10]. Due to the 
widespread prevalence and impact of oxidative stress, there is a huge interest in the development 
of analytical methods that can better monitor its biomarkers in living systems. 
When it comes to the detection of RNOS and their biomarkers, fluorescence derivatization 
has proven to be an invaluable tool due to its high sensitivity, simplicity in data collection and 
manipulation, and its high spatial resolution when combined with microscopic imaging [11].  A 
wide range of fluorescent probes have been developed to directly detect RNOS and small molecule 
biomarkers produced via their activity [11-14]. This dissertation discusses the use of fluorescence 
derivatization to monitor the small molecule by-products of oxidative stress in three prominent 
conditions: epilepsy, inflammation, and traumatic brain injury. Reverse-phase liquid 
chromatography and microchip electrophoresis are used to separate the derivatized biomarkers 
from complex biological matrixes, such as urine, bulk cell lysates, and artificial cerebrospinal 




1.2.  Oxidative Stress 
Under normal physiological conditions there exists a complex biochemical control network 
designed to modulate the amount of RNOS present in the body, which is known as the antioxidant 
defense system [15]. Many of the RNOS responsible for the deleterious effects of oxidative stress 
are free radicals. Radicals are compounds or molecules that possess an unpaired electron that 
makes them less stable and they are therefore usually highly reactive with biomolecules [16]. Free 
radical RNOS include the superoxide radical (O2
•-), hydroperoxyl radical (HO2
•), hydroxyl radical 
(HO•), peroxyl radical (ROO•), nitrogen dioxide radical (•NO2), and nitric oxide (
•NO). Some key 
RNOS are also non-radical species, such as hydrogen peroxide (H2O2), singlet oxygen (
1O2), 
hypochlorous acid (HOCl), the peroxynitrite anion (ONOO-), and peroxynitrous acid (ONOOH) 
[16-18]. 
Endogenously produced RNOS play a pivotal role in several important biochemical 
pathways, such as the production of O2
•- by NADPH oxidase in phagocytes [19] and the synthesis 
of •NO by inducible nitric oxide synthase in macrophage cells [20]. Normally these species are 
kept in check via the antioxidant defense system, which contains enzymatic and non-enzymatic 
pathways that prevent damage by scavenging excess RNOS [21]. When RNOS are produced in 
high concentrations due to disease or trauma, they overcome the ability of these defense systems 
to intercept them, leading to reactions with key biomolecules and the disturbance of natural 
pathways [1]. RNOS have been known to react with DNA [22], proteins [23], and lipids [24]. The 
damage caused by O2
•- and •NO is referred to as nitrosative and oxidative damage, respectively, 
and causes more damage in addition to the original pathophysiological pathway. A selection of the 





The formation of RNOS leads to deleterious damage to biomolecules and biochemical pathways. 
ASS = argininosuccinate synthase; ASL = argininosuccinate lyase; iNOS = inducible nitric 
oxide synthase; SOD = superoxide dismutase. 
  





oxidative stress as it relates to epilepsy, inflammation, and traumatic brain injury will be discussed 
further in the relevant chapters. 
1.3.  Fluorescence 
1.3.1. Theory of Fluorescence 
The term fluorescence was first coined by Sir George Stokes, who used it to describe a 
phenomenon where the wavelength of dispersed light was longer than the wavelength of the 
original light used to illuminate a particular sample [25]. This change in wavelength is now referred 
to as the Stokes shift and is key to the basic theory of fluorescence.  
In fluorescence, an electron is elevated to an excited orbital via absorption of the energy 
from an incoming photon. It can then return to the ground state by the rapid emission of another 
photon. This can be visually demonstrated by a Jablonski diagram, which shows a theoretical 
representation of the ground (s0), first (s1), and second (s2) electronic states of the particular 
compound, as shown in Figure 1.2. When an incoming photon is abosorbed, an electron can be 
excited into the vibrational levels of a higher electronic state. This electron will usually return to 
the lowest vibrational level of the electronic state through a series of non-radiative interactions 
collectively referred to as internal conversion. The electron can then return to the vibrational levels 
of the ground state, emitting a photon of a different energy level, and consequently, a different 
wavelength [26]. This photon is then measured as the fluorescent signal. 
As an excited electron usually goes from the ground state into higher vibrational level of 
the excited state, while fluorescence occurs from the lowest vibrational level of the excited state 
back to the ground state, the energy associated with emission is normally lower than that of 
excitation. This difference in energy is reflected by a longer wavelength in the emitted photon, 




In fluorescence, electrons are excited from the ground state (s0) into the vibrational levels of 
the first (s1) or second (s2) electronic state by the absorption of energy from an incoming 
photon (hv1 or hv2). They will then undergo internal conversion to transition to s1 before 
returning to so via the rapid emission of a photon (hvEM), which is measured as the fluorescent 
signal. 
  





The fluorescence of a particular molecule is often dependent on its aromaticity. The π 
electrons associated with a highly-conjugated structure are more easily excited at energy levels 
correlating to the visible spectrum of light [27]. This makes them suitable for use with common 
excitation sources, such as arc lamps, light-emitting diodes (LEDs), and various laser designs [28].  
Another important factor to consider when studying fluorescence is quantum yield (Φ). 
This is the relationship between the number of photons emitted and the number of photons 
absorbed, with a 1:1 ratio resulting in an Φ of 1.0. The experimental determination of this value is 
key to making quantitative fluorescent measurements [29].  
1.3.2. Fluorescence in Biological Samples 
Fluorescence detection is highly desirable when examining biological samples due to its 
high sensitivity and the specificity that comes from having a specific excitation and emission 
wavelength that is uniqure to the fluorophore of interest, which leads to a measurement that is 
considered background free. Endogenously present fluorescent molecules are known as intrinsic 
fluorophores [30]. Some of the most-studied intrinsic fluorophores are the aromatic amino acids 
tryptophan, tyrosine, and phenylalanine, which all display low fluorescent signals with ultraviolet 
excitation wavelengths [31, 32]. Another common intrinsic fluorophore is the reduced form of the 
coenzyme nicotinamide adenine dinucleotide (NADH) [33]. All four of these compounds display 
low Φ (as shown in Table 1.1) and have a correspondingly low fluorescent signal response. This 
highlights a key issue concerning intrinsic fluorophores: as they are endogenously present, their 
spectrometric properties cannot be easily altered to optimize the response. Also, since such a small 
fraction of biologically-relevant molecules possess are intrinsically fluorescent, they cannot be 




Table 1.1: Examples of the three fluorescent amino acids and one fluorescent coenzyme, along 
with their quantum yield (Φ), excitation maximum (λEX), and emission maximum (λEM) [31-33]. 
Name Structure Φ λEX (nm) λEM (nm) 
Tryptophan 
 
0.13 280 348 
Tyrosine 
 
0.14 274 303 
Phenylalanine 
 
0.024 257 282 
NADH 
 





Extrinsic fluorophores are rationally designed in order to specifically bind to a molecule of 
interest and lend them the desired spectrometric property. These reagents are designed to possess 
a signaling moiety, a biomolecule-specific moiety, and a spacer to connect them [34]. The design 
of an extrinsic fluorophore usually begins with a compound that possesses a high Φ and large 
degree of aromaticity that is fine-tuned to achieve better spectral properties and specific binding 
to the analyte of interest. One such example is xanthene, which has been used as a scaffolding to 
create a wide range of rhodamine and fluorescein derivatives with high Φ values, as shown in 
Figure 1.3 [35, 36]. 
1.3.3. Extrinsic Fluorescent Probes for Biomarkers of Oxidative Stress 
A variety of fluorescent probes have been developed specifically for the direct detection of 
RNOS [11, 13, 14]. However, the short lifetimes and high reactivity of these molecules has given 
rise to doubts about the specificity of these probes and their ability to actually measure RNOS 
concentrations [12, 37]. This has led to the development of probes that derivatize small molecule 
biomarkers of oxidative stress as opposed to the RNOS themselves. 
When looking at carbonyl biomarkers, the most commonly used derivatization reagent is 
2,4-dinitrophenylhydrazine [38]. This compound possesses high specificity for carbonyls, but has 
limited aromaticity and is therefore most commonly used for UV absorbance measurements and 
mass spectrometry [39]. Alterations of its structure gave rise to several fluorescent hydrazide 
species that maintained the high affinity for carbonyls while possessing better spectrometric 
properties [40]. One such derivative is dansylhydrazine (DNSH), which is shown in Figure 1.4. 
This derivatization reagent has the added advantage of binding more readily to aldehydes than 
ketones and has analytical reproducibility [41], fast reaction times (<15 minutes) [42], and good 




Although xanthene is not naturally fluorescent, its structure has been used as the scaffolding to 
create two highly efficient fluorescent reagents: fluorescein (Φ = 0.79) and rhodamine B  
(Φ = 1.0). 
  





Under acidic conditions, dansylhydrazine (DNSH) will react with carbonyls in order to form a 
fluorescent hydrazone derivative. 
  





There exists a literature precedence that suggests oxidative stress can impact amino acid 
concentrations and functionality [16, 23]. A large number of extrinsic fluorescent probes have been 
developed specifically for the determination of amino acids via a reaction with either the primary 
amine or carboxylic acid moiety [44, 45]. A selection of these are shown in Table 1.2, along with 
some key spectrophotometric information and the relevant literature references [46-54]. Of 
particular interest is naphthalene-2,3-dicarboxaldehyde (NDA) [48], a probe designed to improve 
on the common derivatization agent o-phthaldialdehyde (OPA) [47]. This extrinsic probe has the 
added benefit of being a fluorogenic reagent; NDA is non-fluorescent until it reacts with a primary 
amine to form a highly-fluorescent cyanobenz[f]isoindole (CBI) derivative, as shown in Figure 
1.5. This reaction requires the presence of a strong nucleophile to proceed and cyanide (CN) has 
been found to produce the most stable end product. Since NDA itself is not fluorescent it will not 
interfere with the fluorescent signal of the CBI derivatives, simplifying their separation and 
detection. NDA also possesses a high quantum yield (Φ = 0.54) and relatively fast reaction times 
(15-45 minutes). Additionally, the CBI derivatives are more stable than the end product of the 
OPA reaction (t1/2 = 1.5 hours) and lose less than 10% of their overall fluorescence response after 
10 hours [48]. 
1.3.4. Instrumental Considerations for Fluorescence Detection 
One of the most important instrument considerations when using fluorescence detection is 
the excitation source used to provide the original photons. There is a direct relationship between 
the amount of photons absorbed and the amount emitted via fluorescence, meaning that more 
intense light sources will naturally provide a higher signal response [28]. Light sources with a 





Table 1.2: Examples of common fluorescent reagents used for the derivatization of amino acids 
based on a reaction with their amine (NH2) or carboxylic acid (COOH) moieties.  

















340 455 [46, 47] 
9-Fluorenylmethyl  
chloroformate   
(FOMC) 












chloroformate   
(AEOC) 
COOH 5 minutes 0.23 258 418 [50] 
Fluorescein 
isiothiocyanate   
(FITC) 
NH2 2 hours 
0.37 -
0.93 





In the presence of a strong nucleophile (such as cyanide), non-fluorescent naphthalene-2,3-
dicarboxaldehyde (NDA) will react with primary to form a fluorescent cyanobenz[f]isoindole 
(CBI) derivative. 
  





can be used for a variety of fluorescent probes. Some examples of this type of light source are 
Xenon arc lamps [55] and LEDs [56], which both provide a continuous light output over a wide 
range of wavelengths. However, these rarely provide the sensitivity required for biological 
measurements. Lasers can be used to provide monochromatic radiation at a much higher intensity 
and have the potential to be pulsed for different experimental setups [28]. Using a laser as an 
excitation source is commonly referred to as laser-induced fluorescence (LIF).  
1.4.  Analytical Separations 
Although fluorescence can usually provide higher specificity than other spectroscopic 
techniques, the complexity of biological samples usually requires that it be coupled with a method 
of separating out and isolating the various components of the sample matrix. A brief discussion of 
three separation methods pivotal to this work follows.  
1.4.1. Liquid Chromatography 
The term chromatography (literally “color writing”) was coined by Mikail Tswett, who 
used it to describe the separation of pigments from plant extracts [57]. Over the years various 
different chromatographic techniques have been developed for different purposes, such as gas 
chromatography, thin layer chromatography, micellar electrokinetic chromatography, supercritical 
fluid chromatography, and countercurrent chromatography.  
Perhaps one of the best-known chromatographic techniques is liquid chromatography 
(LC). Like all chromatographic techniques, the separation of molecules in LC is dependent on their 
affinity for a stationary phase, which in modern instrumentation consists of micron-sized particles 
packed within a column. A solvent (the mobile phase) is flowed through this packed column at a 
specific flow rate. The length of time it takes for the analytes to elute from the column depends on 




The exact nature of the stationary phase determines the basis of the separation. The most 
common LC separations are dependent on the polarity of the molecules. When the mobile phase 
is less polar than the stationary phase, it is referred to as normal-phase LC. Conversely, when the 
mobile phase is more polar than the stationary phase, it is referred to as reverse-phase LC (RP-
LC). There are many other modes of separation for LC, such as ion affinity, size exclusion, and 
hydrophilic interactions. Examples of some common LC strategies are shown in Table 1.3 [58-
63]. The experiments in this thesis utilize RP-LC, in which the most common stationary phases 
consist of long hydrocarbon chains bound to silica particles, such as octyl (C8) or octadecyl (C18) 
functional groups [63]. 
The efficiency of a chromatographic separation depends on three variables that are related 
using the Knox Equation, shown in Equation 1. Here H represents a theoretical value known as 




3⁄ +  
𝐵
𝑢
+ 𝐶𝑢  (1) 
The efficiency of the separation is highly dependent on the mobile phase velocity (u). The 
multipath term (A) is a measure of the packed nature of a modern chromatographic column and 
accounts for the difference in migration time that arises from the different routes available for 
analytes to travel through the packing material. This is mostly dependent on the particle and 
column dimensions, but the number of paths that the analyte can take will diminish at higher u. 
The longitudinal diffusion term (B) is a measure of band broadening that occurs due to diffusion 
of the analyte within the column. At faster velocities there is less time for the analytes to diffuse 





Table 1.3: Some examples of common separation techniques in LC, including some basic 
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of how well the analytes can diffuse between the mobile and stationary phase to reach an 
equilibrium. At faster velocities there is less opportunity for this equilibrium to be reached, so it is 
directly proportional to u. Since the A/B and C terms directly work against each other, there exists 
an optimal mobile phase velocity at which a chromatographic separation will be most efficient that 
must be experimentally optimized. A graphical representation of the Knox Equation is shown in 
Figure 1.6 that demonstrates this optimal value of u. 
A wide range of detectors can be coupled with LC such as refractive index, evaporative 
light scattering, UV/Vis absorption, electrochemical, conductometric, mass spectrometry, and 
fluorescence detectors [65]. LC has been a dominant analytical tool for decades and has been 
heavily utilized for pharmaceutical and biomedical analyses [66]. 
1.4.2. Capillary Electrophoresis 
Capillary electrophoresis (CE) is a separation method for charged species based on their 
electrophoretic mobility (μe). μe is influenced by the hydrodynamic radius (r) and charge (q) of the 
analyte in question,  as well as the viscosity of the solution (η) as it relates to the frictional 




  (2) 
A CE separation traditionally occurs in a fused silica capillary (with an inner diameter of 
25-250 μm) containing a conductive solution, known as the background electrolyte (BGE). The 
velocity of a particular analyte (v) depends on its affinity towards either the anode or cathode 
depending on its inherent charge. This is a factor of the total electric field strength (E), which is 
established by applying a voltage (V) across the length of the capillary (L). This relationship is 
shown by Equation 3 [68]: 
𝑣 = 𝜇𝑒𝐸 =
𝜇𝑒𝑉
𝐿




This demonstrates the overall impact of the mobile phase velocity (u) on the overall efficiency 
of the separation, as indicated by the height equivalent of a theoretical plate. There exists an 
optimal u at which the most efficient separation can be achieved. 
  





The direction of an ion’s velocity is dependent on its charge; cations will be drawn towards 
the cathode, while anions will be drawn towards the anode. However, in most cases all of the 
analytes are moved in the same direction thanks to a bulk flow known as the electroosmotic flow 
(EOF). The EOF is a result of the interaction between the surface walls of the capillary with the 
BGE. Above a pH of 3, the silica groups on the surface of the capillary walls will become ionized, 
forming a net negative surface charge. A layer of hydrated cations from the BGE will form along 
the walls in response to the negative charge, forming an adsorbed and a diffuse layer of charge. 
These two layers are referred to as the electrical double layer and exist between the bulk BGE 
solution and silica walls. When the voltage is applied across the capillary, the diffuse layer will 
move towards the cathode, producing a bulk flow that will drag the BGE as a whole towards the 
cathode. This bulk flow is usually stronger than the electrophoretic mobility of ions that would 
normally migrate in the opposite direction, carrying all of the ions present in the capillary in the 
same direction to allow for detection [67, 69]. Therefore the overall apparent electrophoretic 
mobility depends not only of that belonging to the ion, but also the electrophoretic mobility of the 
EOF, as shown in Figure 1.7. 
When considering the Knox Equation, CE separations are intrinsically more efficient than 
chromatography. This is because two of the primary terms in that equations (the multipath term 
and mass transfer term) do not apply to CE, given its open columns and lack of stationary phase. 
This means that only the longitudinal diffusion term will influence the efficiency of the separation. 
However, the main weakness of CE is that it fails to separate neutral compounds, since their lack 
of charge means they do not possess a natural μe and will therefore move at the same flow rate at 





The apparent electrophoretic mobility of the analytes (μApparent) depends not only on their 
electrophoretic mobility (μe), but also the mobility of the electroosmotic flow (μEOF). This results 
in all of the analytes being carried in the same direction (pictured here is normal polarity, where 
the EOF flows towards the cathode). 
  





species, usually by using surfactants to create micelles [70]. The neutral species can partition in 
and out of the micelles, which in turn migrate at a different rate than the EOF based on their own 
electrophoretic mobility. The time spent within the micelles will separate the neutral species from 
the EOF, allowing them to be detected separately. Due to the fact that this results in a transition 
between two phases, as is the basis of chromatography, this technique is referred to as micellar 
electrokinetic chromatography. 
1.4.3. Microchip Electrophoresis 
Microchip electrophoresis (ME) was developed in an effort to miniaturize the footprint of 
CE separations. Whereas CE usually occurs in a silica capillary that is 50 – 100 cm in length, ME 
separations occur within microfabricated channels that are typically 5 – 15 cm long. This has the 
obvious benefit of requiring smaller volumes of BGE, as well as using a fraction of the voltage to 
produce the same electric field strength. Additionally, due once again to the smaller separation 
length and channel dimensions (15 μm deep by 50 μm wide), ME separations occur on a much 
faster time scale with less sample diffusion, allowing for better temporal resolution than traditional 
CE systems [71]. Modern microfabrication techniques also allow for the creation of complicated 
features that be directly integrated on the microchip, such as gating, tapered channels, on-chip 
electrodes, and micromixers [72]. Due to these advantages, ME has been extensively employed as 
a separation technique since its introduction in the 1990s [73, 74]. 
A typical ME setup uses two electrodes connected to a high voltage power supply in order 
to generate the electric field. A high voltage is applied to the buffer reservoir, while the reservoir 
at the end of the separation channel is held at ground. This creates an electric field along the 
microfabricated separation channel, which separates the analytes based on their electrophoretic 




polydimethylsiloxane or cyclic olefin copolymer) substrate [75]. The exact methods for fabricating 
an all-glass and a polymer-glass hybrid microchip are discussed in Chapters 3 and 4, respectively. 
The two most basic microchip designs are a simple-t and serpentine, as shown in Figure 
1.8. Three of the four reservoirs in the design are filled with BGE, while the last reservoir contains 
the sample to be analyzed. Two separate electric fields are maintained via the use of two high 
voltage power supplies. One E runs from the BGE reservoir down the length of the separation 
channel, while the second E goes from the sample reservoir to the waste. This results in the 
formation of electrokinetic gate at the junction of these two electric fields that keeps the separate 
flows from mixing. In order to inject a sample plug into the separation channel, the voltage applied 
to the BGE reservoir is temporarily floated, which allows the sample to free flow into the gate 
area. When the voltage is then reestablished a small analyte plug is formed and isolated within the 
separation electric field, at which point the electrophoretic separation can occur. The exact volume 
of the sample plug can be calculated depending on the two field strengths and the length of the 
injection and is highly reproducible [76]. The process of an electrokinetically gated injection is 
shown in Figure 1.9. The length of the sample plug can be calculated using Equation 4 [77]: 
𝑙𝑖 = 𝑡𝑖𝑛𝑗𝐸𝜇𝑒  (4) 
Here, li is the length of the sample plug, while tinj is the injection time. Note that li is 
dependent on the electrophoretic mobility of the analyte, which means that the charge of the ion 
must be taken into consideration when using this injections scheme. 
The most commonly used detection methods for ME are electrochemistry and 
fluorescence. Electrochemistry (usually amperometry) has the advantage of being highly specific, 






Two basic microchip electrophoresis (ME) designs: (A) simple-t; (B) serpentine. 
  





The following process applies to electrokinetic injections for the basic ME device designs shown 
in Figure 1.8: (A) An electrokinetic gate is formed at the junction by the application of two 
separate high voltages; (B) The separation voltage is temporarily floated, allowing the sample 
solution (blue) to fill the junction; (C) The separation voltage is reestablished, isolating a sample 
plug that is carried down the separation channel and electrophoretically separated. 
  





[78]. Solving this usually requires the use of an isolated potentiostat [79], dual separation channels 
[80], or the inclusion of a metal decoupler [81]. Fluorescence, by comparison, couples relatively 
easily with ME due to the optical transparency of most common substrates [82]. Monochromatic 
excitation sources (such as diode lasers) are especially convenient due to the fact that the light can 
be focused at any point within the separation channel with a simple optics setup, allowing the 
detection location to be freely moved for highly sensitive measurements. An example schematic 
of a ME-LIF experimental setup is shown in Figure 1.10. 
1.5.  Chapter Summaries 
The following is a summary of the chapters of this thesis, which employs liquid 
chromatography, microchip electrophoresis, and fluorescence derivatization to monitor by-
products of RNOS overproduction and oxidative stress. 
1.5.1. Chapter 2 
Epilepsy is a condition well-known for causing unprompted seizures in patients. One effect 
of seizures is the overproduction of RNOS, leading to oxidative stress and secondary damage. Free 
radical RNOS will readily react with lipids, leading to lipid peroxidation, a chain reaction in which 
lipids are radicalized and produce more radicals. The byproducts of this process (such as reactive 
aldehyde species) can be used as biomarkers for the extent of lipid peroxidation and oxidative 
stress. In this chapter, reactive aldehydes are derivatized with DNSH to produce hydrazone 
derivatives, which are subsequently separated using RP-LC and detected via their fluorescence. 
1.5.2. Chapter 3 
Inflammation plays a role in a host of different disease states. This is partially due to the 





The wavelengths of the diode laser and filters can be modified for the fluorescent probe of 
interest. 
  





synthase (iNOS). Over-activation of these cells will result in an excess of •NO, which will lead to 
oxidative stress. Carnosine is an endogenous dipeptide that is known to show antioxidant 
properties. In this chapter, the uptake of carnosine into macrophage cells under pro-inflammatory 
conditions is investigated. Carnosine is monitored in cell lysates following NDA/CN derivatization 
and separation from other amino acids by use of ME-LIF. 
1.5.3. Chapter 4 
Traumatic brain injury (TBI) is the most common type of neurotrauma in the world and is 
caused by blunt-force trauma to the brain. Patients with severe TBIs require their skulls to be 
opened to relieve pressure, which also allows medical professionals to use microdialysis sampling 
(MD) to gauge their neurochemical health and evaluate treatment. Excitatory amino acids (EAAs) 
are a key factor in post-injury health for TBI patients that can lead to neurotoxicity, so being able 
to monitor their concentration will help with therapeutic treatment. In this chapter, an overall MD-
ME-LIF system was optimized with on-line derivatization of EAAs using the NDA/CN reaction. 
1.5.4. Chapter 5 
This chapter summarizes the progress on these three research projects to date. It also 
provides immediate and long-term future directions. These include probing different brain regions 
with epileptic seizures, further studies of iNOS activity in macrophage cells, and improvements in 
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Detection of Reactive Aldehyde Biomarkers as a Measure of Lipid Peroxidation Following 
Epileptic-like Seizures 
2.1. Epilepsy 
A patient is officially diagnosed with epilepsy after experiencing two or more unprovoked 
seizure events over the course of their lifetime. This neurodegenerative disease is extremely 
prevalent, with an estimated 45 million people affected worldwide. The exact cause of new-onset 
epilepsy is unknown in a majority of patients (62%), while others develop the condition after 
strokes, head trauma, tumors, and other conditions [1]. Up to a third of all patients diagnosed with 
epilepsy are non-responsive to currently available antiepileptic drug therapies [2]. Furthering our 
understanding of epilepsy and its underlying mechanisms is the first step in developing new 
therapeutics to help combat this disease.  
Recent research has shown that epileptic seizures result in the overproduction of RNOS, 
leading to oxidative stress and damage. The subsequent neurotoxicity can in turn make a patient 
more susceptible to seizure initiation in the future [3]. It is therefore of pivotal importance to 
examine and limit oxidative stress in relation to this neurodegenerative disease. 
2.1.1. Neuronal Activity and Signaling 
Neurons are the primary cells in the central nervous system responsible for transmitting 
nerve impulses from one cell to the next. This occurs in a space between the synaptic knob of one 
neuron and the dendrite of an adjacent neuron known as the synaptic cleft. Impulses are carried 
along the neuron due to differences in potential generated by ion gradients. A neuron has a resting 




naturally low in Na+ and Cl-, while high in K+, compared to the surrounding extracellular fluid 
(ECF) [4].  
Specific proteins known as ion channels exist that allow ions such as Na+, Cl-, K+, and Ca2+ 
to cross the cell membrane in response to a physiological stimulus (such as a potential change or 
neurotransmitter response). This process is referred as opening the gates of the ion channel [5]. 
When the cell membrane is depolarized (to around -40 mV) it opens up the gate of Na+ channels, 
which results in an increase of Na+ permeability and an influx of Na+ into the neuron from the 
ECF. When the depolarization reaches a membrane potential of approximately +30 mV, the Na+ 
channels will close and K+ channels will open, which will return the membrane back to its resting 
potential via the release of K+ into the ECF, a process known as repolarization [6]. This overall 
rise and fall of the membrane potential is known as the action potential and is responsible for the 
propagation of nerve impulses along the axon of a neuron, as shown in Figure 2.1. When action 
potentials reach the synaptic knob, they cause the secretion of neurotransmitters into the synaptic 
cleft. Some common neurotransmitter families include cholinergic agents, catecholamines, amino 
acids, and peptides, among others [4]. 
2.1.2. Excitatory and Inhibitory Mechanism of Seizures 
Several amino acids (and derivatives) function as neurotransmitters. This includes alanine, 
aspartate, cystathione, glycine, glutamate, histamine, proline, serotonin, taurine, tyrosine, and γ-
aminobutyric acid (GABA) [4, 7]. Dysfunctions in these amino acid neurotransmitters has been 
linked to several diseases impacting the central nervous system [8]. This is especially true of 
epilepsy because glutamate and GABA are the most abundant excitatory and inhibitory 
neurotransmitters in the brain, respectively. An imbalance of these two neurotransmitters is one of 




(A) The resting potential of the cell membrane is due to the differences in ion concentration 
between the inside and outside of the axon; (B) Gates on the Na+ ion channels open up, causing 
depolarization via an influx of Na+ into the cell; (C) When the influx of Na+ stops, the gates on 
K+ ion channels will open, causing repolarization via the expulsion of K+ into the ECF; (D) The 
resting potential is re-established, allowing for the continuation of the action potential down the 
length of the axon. 
  





The prolonged release and overproduction of glutamate lead to excitation of the ionotropic 
receptors responsible for its regulation, such as the N-methyl-D-aspartate (NMDA), α-amino-3-
hydroxy-5-methyl-4-isoxasole-propionic acid (AMPA), and kainite receptors. This will open the 
gate of Ca2+ and Na+ ion channels, leading to an influx of these ions. These signals are normally 
inhibited via the opening of K+ or Cl- channels by GABA to repolarize the neuron. However, when 
glutamate is overproduced, these inhibitory mechanisms are unable to maintain this balance. This 
results in constant neuronal transmission that leads to excitotoxicity, forcing cells to undergo 
apoptosis and releasing more glutamate into the synaptic cleft [10]. The continuous firing of the 
affected neurons will produce a wave of synchronous neuronal activity; in other words, a seizure. 
2.1.3. Chemically Induced Seizure Models 
When examining epilepsy in a laboratory setting, it becomes necessary to find a method to 
consistently and reproducibly induce similar seizures in an animal model. There are two primary 
approaches to this, depending on the type of seizure desired: a focal or general seizure. Focal 
seizures are defined as those that both originate and remain within one hemisphere of the brain, 
and are thus achieved through local dosing at the desired location. Conversely, a general seizure 
results in neuronal activity that spreads across the distributed networks of both brain hemispheres, 
and are achieved through the bolus dosing or constant infusion of a convulsant [11]. 
Our group has previously developed a steady-state chemical seizure model in rodents using 
3-mercaptopropionic acid (3-MPA). This compound inhibits the functionality of glutamic acid 
decarboxylase (GAD), the enzyme responsible for converting glutamate to GABA, as shown in 
Figure 2.2. The subsequent imbalance between the excitatory and inhibitory neurotransmitters in 





Under normal physiological conditions, the balance between the excitatory (glutamate) and 
inhibitory (GABA) amino acid neurotransmitters is maintained by the glutamic acid 
decarboxylase enzyme (GAD). 3-mercaptopropionic acid (3-MPA) competeitively reacts with 
GAD, leading to an overproduction of glutamate and chemically induced seizures. 
  





pharmacokinetics [12] and correlating concentration of amino acid neurotransmitters [13] in the 
3-MPA seizure model have previously been explored in detail using microdialysis sampling. 
2.1.4. Epileptic Seizures and Oxidative Stress 
Although several studies have correlated an increase RNOS concentrations with epileptic 
seizures, the exact mechanism linking them is not fully understood. Several different hypotheses 
have been suggested for the overproduction of RNOS related to this condition [3]. This includes 
the production of RNOS through mitochondrial dysfunction [14] and the alteration of 
cyclooxygenase and lipoxygenase functionality [15]. This is compounded by the fact that the brain 
is heavily susceptible to oxidative stress and damage due to the high demand for oxygen, low 
concentration of endogenous antioxidants in the ECF, and abundance of polyunsaturated fatty 
acids (PUFAs) [16, 17]. The secondary damage caused by oxidative stress can sometimes prove 
more harmful than the initial seizure event itself and make patients more susceptible to the onset 
of additional seizures [3]. 
Free radical RNOS are primarily responsible for this damage, especially in the case of 
PUFAs, where they will readily react with the biomolecule to alter their structure and functionality 
[18]. This can result in a self-propagating chain reaction in which RNOS create radical species, 
which in turn beget the formation of new radicals; this process is referred to as lipid peroxidation. 
2.2. Lipid Peroxidation 
2.2.1. Onset and Mechanism of Lipid Peroxidation 
PUFAs are a subgroup of lipids that consist of long-chain carboxylic acids with more than 
one carbon-carbon double bond in their backbone. PUFAs can be separated into categories 
depending on the distance between the methyl-end of the backbone and the final double bond, 




the number of double bonds (Z) are also indicated by Y:Z. For example, arachidonic acid is labeled 
as a 22:4 (ω-6) PUFA; this means that its carbon backbone is twenty-two carbon molecules long, 
has four double bonds, with the final double bond at the sixth carbon from the methyl end. Some 
further examples of PUFA naming conventions are shown in in Table 2.1. 
PUFAs are highly susceptible to attack by RNOS. The process by which lipid peroxidation 
occurs can be divided into three steps: initiation, propagation, and termination, as shown in Figure 
2.3. In the initiation step, a RNOS (usually OH•) will abstract hydrogen from a PUFA, resulting in 
the formation of water and a lipid radical (L•). Propagation will then occur when the lipid radical 
rapidly reacts with molecular oxygen to form a lipid peroxy-radical (LOO•). This will in turn 
scavenge protons off of other lipids, forming a lipid hydroperoxide and another lipid radical. This 
lipid radical will react with molecular oxygen to restart this process, leading to a cascade of radical 
formation. In the termination step, various antioxidants (such as vitamin C or  
glutathione) [19, 20] detoxify these lipid hydroperoxides to form stable lipid alcohols and other 
small molecules. 
2.2.2. Reactive Aldehyde Species as Biomarkers 
The breakdown of lipid hydroperoxides in the termination stage of lipid peroxidation will 
produce a large number of aldehyde species. There is a great deal of literature using these reactive 
aldehyde species as small molecule biomarkers of lipid peroxidation and, consequently, oxidative 
stress and damage. Three of the most commonly examined are 4-hydroxynonenal, 
malondialdehyde, and acrolein [21]. The structures of these compounds are shown in Figure 2.4. 
4-Hydroxynonenal (4-HNE) is formed during lipid peroxidation due to the beta-cleavage 





Table 2.1: Naming conventions and corresponding structures of the PUFAs primarily responsible 
for the formation of reactive aldehyde species. 


















Lipid peroxidation is a self-propagating chain reaction that ends in the formation lipid 
bicycloendoperoxides and lipid alcohols. The propagation occurs via the removal of protons 
















shown that 4-HNE disturbs mitochondrial functionality, resulting in cytotoxicity, as well as 
reacting with proteins, phospholipids, and DNA in vivo due to its high reactivity with thiol and 
amino groups [21, 23]. 4-HNE is one of the most heavily studied biomarkers of lipid peroxidation 
due to its toxicity and the fact that it acts as a specific marker of oxidative stress. 
Malondialdehyde (MDA) primarily forms from PUFAs that will degrade into 
bicycloendoperoxides during the propagation steps of lipid peroxidation, such as ω-6 arachidonic 
acid (20:4) and ω-3 docosahexaenoic acid (22:6). These unstable bicylcoendoperoxides will then 
thermally degrade to form MDA [24]. MDA has a pair of  aldehyde moieties will undergo reactions 
with nucleophilic centers on biomolecules, giving it a high potential to cause toxicity and 
mutagenicity [25]. This reactivity has also been exploited to detect MDA via the use of 2-
thiobarbituric acid (TBA) to form a fluorescent product. However, TBA will also react with other 
endogenous dialdehydes and pyrimidine, making the assay non-specific [26].  
Several 2-alkenal species can be produced via the oxidation of PUFAs by molecular 
oxygen, including 2-pentenal, 2-heptenal, 2-octenal, and 2-nonenal. By far the most toxic of these 
is acrolein, a component of cigarette smoke and byproduct of overheating oils [21]. Acrolein is an 
incredibly strong electrophile and shows higher reactivity than 4-HNE or MDA with biomolecules 
containing thiol or amine moieties. Due to its high reactivity, acrolein is most often detected in 
biological samples after binding to the cysteine residues of proteins [27]. 
Despite the importance of these three reactive aldehyde species, there are few studies in 
the literature examining them simultaneously in a biological system. By taking advantage of their 
shared aldehyde moieties, a fluorescent derivatization assay can be used to simultaneously detect 





2.3.  Methods 
2.3.1. Materials and Reagents 
HPLC-grade acetonitrile (ACN) and glacial acetic acid were purchased from Fisher 
(Waltham, MA). Potassium dihydrogen phosphate (KH2PO4), MDA (malondialdehyde 
tetrabutylammonium salt), DNSH (bioreagent, suitable for fluorescence, ≥ 95%), and acrolein 
(analytical standard) were obtained from Sigma-Aldrich (St. Louis, MO, USA). 4-HNE was 
purchased from Cayman Chemical (Ann Arbor, MI, USA). All solutions were prepared using 
nanopure water from a Labconco Water Pro Plus purification system (Kansas City, KS, USA). 
2.3.2. Fluorescent Derivatization of Aldehydes 
Dansylhydrazine (DNSH) is a derivatization reagent that was originally developed for the 
detection of carboxylic acids [28]. This compound will react with any target containing a carbonyl 
moiety under acidic conditions [29], although past work has shown it will bind more readily to 
aldehydes than ketones [30]. It has been used for this purpose in tissue [31] and air samples [32, 
33]. In acidic conditions, DNSH will react with aldehydes to form a fluorescent hydrazone 
derivative, as was shown in Figure 1.4. 
The method used to derivatize the aldehydes was adapted from the literature [34, 35]. 
DNSH was dissolved in a solution of ACN containing 0.1% glacial acetic acid at a concentration 
of 100 mM and stored at 4 °C. This derivatization solution was reacted with the sample in a 1:10 
ratio by volume and allowed to proceed for 20 minutes at 50 °C before injection into the 
chromatographic system. 
2.3.3. Liquid Chromatography System 
Sample analysis was performed using an LC-fluorescence system that consisted of a 




Detector. A Phenomenex Gemini C18 column (100 × 2.00 mm, 3 µm particle) with matching guard 
column (4 × 2.0 mm) was used for the separation. An underfill injection of 10 µL was used in a 
20 µL Rheodyne® stainless steel injection loop. An isocratic mobile phase containing 12 mM 
KH2PO4 (pH = 7.7) buffer and acetonitrile was employed for the separation. The acetonitrile 
(ACN) percentage in the mobile phase was determined experimentally and is discussed in more 
detail in the Discussion section. 
2.3.4. Solid Phase Extraction 
Solid phase extraction (SPE) was performed using a Sep-Pak C18 obtained from Waters 
Corporation (Milford, MA) and a vacuum manifold from Supelco Analytical (St. Louis, MO). SPE 
was use to preconcentrate the hydrazone derivatives following the DNSH reaction. The Sep-Pak 
cartridges were conditioned with 3 mL of ACN and 3 mL of H2O before being loaded with 1 mL 
of derivatized sample. This was washed with 5 mL of H2O and an experimentally determined 
ACN:H2O solution, the composition of which is mentioned in the Discussion section. The 
hydrazone derivatives were eluted in 2 mL ACN, which was evaporated under a steady stream of 
argon gas while being held at 25 °C with a heating block. The solid residue was reconstituted in 
50 µL of 50:50 ACN:H2O before being injected on the LC system.  
2.3.5. Animal Seizure Model 
Animal experiments were performed using Wistar rats from Charles Rivers Laboratories, 
Inc. (Wilmington, MA) that were in the weight range of 300-400 g. The rats were housed in 
temperature- and humidity-controlled rooms with a 24-h light/dark cycle and free access to food 
and water.  Forty-eight hours prior to dosing, the animals were transferred to a metabolic cage on 
a rodent workstation, both from Bioanalytical Systems, Inc. (West Lafayette, IN). Urine was 




0.22 µm polyethersulfone syringe filter. The first 0.5 mL of urine was used to wet the filter and 
discarded. The remaining urine was filtered into a 20 mL scintillation vial and stored at -80 °C 
until they could be derivatized and analyzed. 
Seizure model animals received a 5 mL bolus interperitoneal (i.p.) dose of 50 mg 3-
MPA/kg body weight, and were observed to confirm seizure activity. The 3-MPA solution was 
prepared by diluting the proper volume of reagent per rat body weight with sterile 0.9% saline to 
a total volume of 5 mL. Control animals received a 5 mL bolus i.p. dose of 0.9% saline. Rats were 
housed in the metabolism cage for a total of 120 hours. The animal experiments described here 
follows the principles and regulations stated in the Guide for the Care and Use of Laboratory 
Animals and was approved by the University of Kansas Lawrence Institutional Animal Care and 
Use Committee.  
2.4.  Discussion 
2.4.1. Dansylhydrazine Derivatization Optimization 
Previous methods have used DNSH to measure acrolein, and the derivatization procedure 
used here was based on those findings [34]. The reaction solution contained 100 mM of DNSH 
and 0.1% glacial acetic acid to promote the formation of the hydrazone derivatives. 
Although hydrazone derivatives have previously been detected on an LC system an 
excitation (EX) wavelength of 240 nm and an emission (EM) wavelength of 470 nm, this was 
using a mobile phase with a different organic composition (32% ACN) and samples fully dissolved 
in ACN [35]. Using a different mobile phase composition (50% ACN with 12 nM KH2PO4) 
resulted in a much lower fluorescence intensity, which required the EX and EM wavelength 
maxima to be determined experimentally. This is due to the influence of the sample matrix on the 




the reaction with the aldehyde species, a fluorometer could not be used for this analysis. This is 
because the large molar concentration of DNSH obscured the signal from the derivatized products. 
Instead the optimal wavelengths were determined using the chromatographic separation 
with a variable wavelength fluorescence detector. The maximum EM wavelength was determined 
first by exciting at 240 nm and changing the EM wavelength, zeroing in on the maximum 
fluorescence response, which was found to be 550 nm. A similar experiment was conducted to 
identify the maximum EX wavelength, where the emission was kept at 550 nm, in order to find 
the optimal EX wavelength of 250 nm. 
2.4.2. Chromatographic Separation 
The excess DNSH present in the reaction sample also complicated the chromatographic 
separation, as the polar reagent was present early in the separation as a large peak. The mobile 
phase composition was optimized to obtain sufficient resolution between the excess DNSH and 
the most polar of the aldehydes of interest, acrolein. 
Starting with an ACN composition of 60%, the organic percentage of the mobile phase was 
varied by 10% until adequate resolution was obtained between the acrolein and residual DNSH 
peaks as shown in Figure 2.5. This was determined to be at a mobile phase consisting of 50% ACN 
with 12 mM KH2PO4 (pH = 7.7). These experiments were performed using standards prepared in 
mobile phase to avoid peak broadening due to a mismatch in organic content between the sample 
matrix and mobile phase.  
Under these conditions, all three dansyl derivatives displayed high linearity over a 






The resolution between the acrolein and excess DNSH peaks was highly dependent on the 
organic composition of the mobile phase. The final mobile phase consisted of 50% ACN with 
12 mM KH2PO4 (pH = 7.7). 
  





micromolar range (2.6 and 3.8 µM, respectively), while HNE had LOD in the nanomolar range 
(122 nM). The final separation is shown in Figure 2.6, with the corresponding figures of merit in 
Table 2.2. 
2.4.3. Solid Phase Extraction Pre-Concentration 
Since initial results indicated the LOD of this method was insufficient for use in urine 
samples (where concentrations were estimated to be near 1 µM), SPE was used as a pre-
concentration method. In order to properly elute the hydrazone derivatizes off of the SPE cartridge, 
the proper organic composition needed to be optimized to minimize the loss of analyte and 
minimize interferences. The optimal elution solvent was found to be a 70:30 ACN:H2O solution.  
The pre-concentration procedure was optimized by running a series of standards near the 
expected biological concentration range through the SPE procedure and comparing the signal 
response to non-treated standards at twenty times the concentration. Following the SPE procedure 
mentioned in the Methods section, this should result in a 20-fold concentration of the derivatized 
analytes. This process showed a 96% agreement between the pre-concentrated and untreated 
standards. 
The reproducibility of the SPE procedure was also evaluated using standards. 4-HNE and 
MDA exhibited a recovery of 109 ± 5% and 110 ± 25%, respectively. The % RSDs for the recovery 
of these analytes from urine samples were 17.6% and 8.0%, which is considered an acceptable 
margin of error for biological samples, as variations in specific analyte concentrations can be 
expected between different animals and samples. The twenty-fold enrichment due to the sample 
treatment led an improvement in the LOD for final values of 6.1 nM for 4-HNE and 192 nM for 













Table 2.2: Figures of merit for the separation of the reactive aldehyde hydrazone derivatives.  
 Acrolein 4-HNE MDA 
LOD (µM)            
(S/N = 3) 
2.6 0.122 3.8 
Resolution (R) 0.94 6.4 2.1 
Theoretical Plates (N) 2125 1344 1104 
Linearity (R2) 0.976 0.991 0.961 





Figure 2.7. Although there was a peak that eluted close to that of 4-HNE, it was decided that the 
resolution between them (R = 0.71) was sufficient for quantitation. 
2.4.4. Animal Seizure Model 
This method was used to monitor the concentration of the three reactive aldehydes of 
interest in urine samples before and after an oxidative stress event. An epileptic-like seizure was 
chemically induced using 3-MPA, with urine collected in 12 hour intervals. Unfortunately, MDA 
could not be detected in enough of the urine samples to make any conclusive statements. Past 
studies in our group have studied this compound in the brain following an epileptic seizure, but 
there was no information regarding its systemic response [36]. 
When analyzing urine samples, there was a reproducible trend of shifting retention times 
in subsequent separations. This was due to the gradual adsorption of biological compounds to the 
guard column cartridge. This irreproducibility in retention times was addressed by running fresh 
standards between each derivatized urine sample to validate the peak identities, as well as replacing 
the guard cartridge between each individual animal study. 
The overall procedure of the animal experiments is shown in Figure 2.8 that includes the 
sample preparation and chromatographic system. 
2.4.5. Importance of Seizure Timing on Aldehyde Concentrations 
Seizures induced during the transition from the dark to light period were referred to as the 
morning dose. As seen in Figure 2.9, there was a noticeable circadian rhythm in the concentration 
of aldehydes in urine samples, with acrolein possessing higher concentrations during the light 
period and 4-HNE possessing higher concentrations during the dark period. These results have not 





Although only an acrolein peak is present in the plain urine samples (A), 4-HNE and MDA 
peaks are easily visible following the SPE pre-concentration procedure (B). 
  










to basal levels in the 12-h period immediately following the event (p = 0.024), correlating with 
previous findings for MDA. Conversely, 4-HNE levels were not significantly impacted (p = 0.26). 
This suggests there is an unexplored difference in the metabolism of these reactive aldehydes in 
vivo. 
A second set of experiments was conducted to guarantee that the rise in acrolein 
concentration was not due to artificial inflation from the circadian cycle. In these studies, the 
seizure was induced during the transition from the light to dark period (referred to as the evening 
dose). Similar results were observed regarding the circadian nature of aldehyde concentration, the 
elevation in acrolein levels (p = 0.069), and the lack of response from 4-HNE (p = 0.15), as shown 
in Figure 2.10. Although the rise in acrolein was not significantly different at the 95% confidence 
interval, there is still a clear trend present from these experiments. 
2.5.  Conclusion 
A LC-fluorescence method was developed for the detection of reactive aldehyde 
biomarkers of lipid peroxidation using SPE pre-concentration to prepare bulk biological samples, 
such as urine. The LOD obtained were sufficient to detect two important biomarkers, 4-HNE and 
acrolein, in 12-h urine samples in a rodent model of epilepsy. These compounds follow a 
previously unreported circadian cycle that corresponds to the light/dark cycle of the animal. 
Furthermore, acrolein displayed a significant increase in concentration following a chemically 






Although both aldehyde species demonstrate a circadean cycle, only acrolein (A) shows an 
increase in basal concentration following the induced seizure (t = 0 h), while 4-HNE (B) levels 
do not show any significant change. *p = 0.024 **p = 0.26 
 





Acrolein (A) still shows a rise in response while 4-HNE (B) does not. *p = 0.069 **p = 0.15 
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Chapter 3:  
Measuring Carnosine Uptake in Macrophage Cells under Pro-Inflammatory Conditions as 
a Measure of its Antioxidant Properties 
3.1.  Inflammation and the Immune Response 
Inflammation is a complex biological process that occurs after exposure to a wide variety 
of harmful environmental stimuli such as infections, allergens, chemicals, radiation, obesity, 
alcohol, tobacco, and chronic diseases [1]. Acute (or therapeutic) inflammation is actually caused 
via the endogenous immune response and is used to help ward off infections over a short period 
of time [2]. Chronic inflammation, on the other hand, can prove extremely deleterious and harmful 
to the body and has been linked to a wide number of diseases, including tumor formation in 
prominent types of cancer, such as pancreatic [3] and breast [4] cancer. Acute inflammation is 
caused by the production of nitric oxide (NO•) in order to eliminate pathogens; in cases of chronic 
inflammation, this also leads to oxidative stress [5]. A better understanding of how endogenous 
antioxidants help mitigate the concentration of RNOS produced by inflammatory pathways could 
provide new therapeutic pathways for the treatment of chronic inflammation. 
3.1.1. The Immune Response and Acute Inflammation 
Macrophages are immune cells that are responsible for the primary response to pathogens, 
as well as serving several other roles related to the immune response [6]. The phagocytic activity 
of macrophages is promoted by lymphocytes such as T helper (Th) cells and natural killer (NK) 
cells that respond to specific antigens [7]. Macrophages can be activated via different pathways 
for different functionalities. Classically activated macrophages (or M1) are in response to the 
production of the cytokine interferon gamma (INF-γ) from Th1 cells and NK cells or the presence 




response to the production of interleukin-4 (IL-4) by Th2 cells and granulocytes [8, 9]. 
Macrophages can also be directly activated by bacterial endotoxins such as lipopolysaccharide 
(LPS) [10]. M1 macrophages protect against microbial activity and bacterial pathogens, while M2 
macrophages deal with tissue repair, parasitic infections, and tumors [8, 9]. A third population of 
macrophages can be activated by interleukin 10 (IL-10) and serve regulatory and anti-
inflammatory functions [11]. These various modes of macrophage activation are shown in Figure 
3.1. 
M1 activated macrophages are pivotal in host defense against microbial pathogens. This is 
accomplished by the activation of the protein inducible nitric oxide synthase (iNOS), which 
converts arginine to citrulline in order to produce NO• [5]. The production of NO• is meant to result 
in cytotoxic effects on bacteria and protozoa. However, NO• is highly reactive and will just as 
readily result in the nitrosation and nitration of important biomolecules. The non-specificity of 
NO• directly causes acute inflammation via these reactions, and long-term overproduction by M1 
activated macrophages will also result in chronic inflammation and oxidative stress [12]. 
Previous studies have shown that macrophages can be activated in an in vitro environment 
that mimics the natural progression of the immune response. Specifically, stimulating RAW 264.7 
murine macrophages with a combination of INF- γ and LPS have been shown to increase iNOS 
activity by increasing RNOS production [13]. 
3.1.2. Oxidative Stress from the Immune Response 
One of the primary sources of oxidative stress following the immune response is the 
reaction of NO• with superoxide (O2
•-) to produce peroxynitrite (ONOO-). Cellular O2
•- is mainly 











1-4 % of molecular oxygen is incompletely reduced to O2
•- [14]. ONOO- is cytotoxic and leads to 
further damage to biomolecules [15]. ONOO- can also be protonated to form peroxynitrous acid, 
which in turn leads to the formation of another highly reactive RNOS: the hydroxyl radical [16]. 
This overall process was previously shown in Figure 1.1. 
NO• can act as a further precursor of oxidative stress due to its reactivity with endogenous 
antioxidant enzymes. For example, superoxide dismutases (SOD) are a family of enzyme that 
responsible for scavenging excess O2
•- intracellularly and reducing it to hydrogen peroxide and 
water, a process that is normally highly efficient due to the intracellular abundance of SOD [17]. 
However, NO• will competitively react with SOD, restricting this activity and directly leading to 
hgher intracellular concentrations of O2
•- and ONOO- [18].  
One therapeutic strategy for conditions such as chronic inflammation is using antioxidants 
in order to bolster the body’s natural defense systems [19]. This has led to a high demand for 
studies investigating molecules that exhibit antioxidant properties that could possibly scavenge 
RNOS before they result in deleterious effects. 
3.2.  Carnosine 
One endogenous biomolecule that has demonstrated antioxidant properties and is believed 
to be a part of the antioxidant defense system is carnosine, a dipeptide composed of β-alanine and 
L-histidine. Carnosine was first discovered in 1900 in meat extract and has since been heavily 
studied due to its natural presence in several mammalian tissues, including the central nervous 
system, skeletal muscles, and the lens of the eye in humans [20]. Carnosine is produced via the 
enzyme carnosine synthase, an ATP-dependent ligase that combines its constituent peptides [21]. 
It can also be degraded by the enzyme carnosinase, re-forming these two pepetides [22]. The 










3.2.1. Biochemistry of Carnosine 
Carnosine serves a wide host of functions in the body [23]. At physiological pH (7.4) it is 
zwitterionic, allowing it to function as an endogenous buffering species. It will also readily form 
complexes with transition metal ions, the most biologically relevant of which are copper [24] and 
zinc [25]. Carnosine has also been shown to regulate macrophage functionality, although the exact 
mechanism of this is not yet fully understood [26]. 
3.2.2. Antioxidant Properties of Carnosine 
Carnosine and its structurally related compounds have demonstrated antioxidant properties 
[26, 27]. Its specific role as a neuroprotective antioxidant have also been investigated and found 
that it will readily scavenge free radical RNOS that could otherwise cause oxidative stress [28]. 
The dipeptide has been shown to scavenge both O2
•- [29] and HO• [30], two free radical RNOS 
whose role in oxidative stress was discussed earlier. It has also been shown to scavenge peroxyl 
radicals, one of the byproducts of lipid peroxidation that leads to the propagation of the radical 
chain reaction [31].  
In vitro and in vivo experiments have been conducted to determine the effects of carnosine 
on pathologies known to cause oxidative stress and damage. This includes Alzheimer’s disease 
[32], Parkinson’s disease [33], diabetes [34], atherosclerosis [35], and ischemic stroke [36]. The 
exact mechanism by which carnosine influences these pathologies is not completely understood, 
but is thought to be primarily due to its antioxidant, chelating, and anti-glycation functions [20]. 
A better understanding of its antioxidant properties could allow progress to be made towards 





Investigating the inherent uptake of carnosine by unstimulated macrophage cells will 
provide information regarding its normal concentration in the body. If the M1 activation of these 
 macrophages alters their ability to uptake carnosine, it will also indicate whether or not its 
antioxidant properties are being exploited in order to reduce chronic inflammation. 
3.3.  Methods 
3.3.1. Rational for Separation Selection 
Microchip electrophoresis (ME) provides many benefits that make it a desirable technique 
for bulk cell lysate analysis that has led to its use for related studies [13, 37, 38]. The short length 
of microfluidic channels and the high field strengths applied lead to rapid separations, high 
throughput, and minimal sample dilution. Additionally, electokinetic injections allows for 
reproducible and small-volume sample injections, which is desirable when studying biological 
samples such as cell lysates. This also allows for more separations to be conducted using the same 
patch of cells to guarantee the reproducibility of the results. The inherently high conductivity of 
the sample matrix also pairs well with ME, where the background electrolyte (BGE) can be 
modified to match, making it unnecessary to desalt the lysate [39]. Finally, the compatibility 
between ME and laser excitation sources for fluorescence allows for the detection of molecules in 
cell lysate at physiologically relevant concentrations. 
3.3.2. Materials and Reagents 
Murine RAW 264.7 cells (ATCC® TIB71™), Dulbecco’s Modified Eagle’s Medium 
(DMEM), phenol red-free DMEM, fetal bovine serum (FBS), and penicillin/streptomycin 
antibiotic solution were purchased from American Type Culture Collection (ATCC, Manassas, 
VA, USA). AZ1518 precoated glass substrates were purchased from AZ Electronic Materials Corp 




Materials (Somerville, NJ). Chrome etchant was supplied by Cyantek (Fremont, CA). L-carnosine, 
sodium cyanide (NaCN), anhydrous dimethyl sulfoxide (DMSO), phosphate-buffered saline 
(PBS), Trypan blue solution, lipopolysaccharides (LPS), Triton X-100, and bovine serum albumin 
(BSA) were all supplied by Sigma-Aldrich (St. Louis, MO, USA). Sodium hydroxide (NaOH), 
hydrochloric acid (HCl), hydrofluoric acid (HF), AlconoxTM powdered detergent, 25 mL 
polystyrene culture flasks, boric acid, and ethanol (95%) were obtained from Fisher Scientific 
(Pittsburgh, PA, USA). Interferon-γ (IFN-γ) was supplied by Calbiochem (Gibbstown, NJ, USA). 
Naphthalene-2,3-dicarboxaldehyde (NDA) was obtained from Invitrogen (Carlsbad, CA, USA). 
Polyethersulfone (PES) membrane (3K) was purchased from VWR International (West Chester, 
PA, USA). C-Chip disposable hemocytometer was purchased from Bulldog Bio, Inc. (Portsmouth, 
NH, USA). All water used was Ultrapure (18.3 MΩ cm) (Milli-Q Synthesis A10, Millipore, 
Burlington, MA, USA). 
3.3.3. Preparation of Carnosine Standards and Background Electrolyte 
The sodium borate background electrolyte (BGE) was prepared from 20 mM boric acid 
titrated to pH 9.2 via the addition of 0.1 M NaOH. Carnosine standards were prepared at 0.5 M in 
water before further dilution in BGE to the desired concentration (such as the 100 µM solution 
used in the standard addition experiments). The carnosine standards were prepared weekly and 
stored at -20 °C to avoid degradation. 
3.3.4. Fluorescent Derivatization of Carnosine and Intracellular Amines 
Naphthalene-2,3-dicarboxaldehyde (NDA) is a fluorogenic reagent designed for the 
derivatization of primary amines such as carnosine [40] that was previously discussed in Chapter 
1. NDA will react with primary amines in the presence of a strong electrophile, such as cyanide, 




For this study, NDA was prepared at a concentration of 5 mM in ACN. NaCN was prepared 
at a concentration of 10 mM in H2O. Both of these derivatization solutions were prepared weekly, 
stored at 4 °C, and protected from light exposure to prevent photobleaching. 
Standards were derivatized by diluting the appropriate volume of 0.5 M carnosine with 
BGE to a final volume of 1540 µL to achieve the desired final concentration. Thirty microliters of 
the NDA and NaCN solutions were sequentially added with mixing, after which the reaction was 
allowed to proceed for at least 30 minutes at room temperature while being protected from light. 
For cell samples, 40 µL of filtered cell lysate was diluted with 100 µL of BGE before the addition 
of 30 µL of the NDA and NaCN solutions, followed by mixing and a thirty minute reaction time 
in the dark. 
For the standard addition experiments, 20 µL of native cell lysate was divided into four 
portions. The appropriate volume of a 100 µM carnosine standard (diluted in BGE) was added to 
the lysate to produce final concentrations of 1, 2.5, and 5 µM in the samples. They were then 
diluted with BGE to a final volume of 70 µL before the addition of 15 µL of the NDA and NaCN 
solutions. This reaction was also allowed to proceed for at least thirty minutes while protected 
from light exposure. 
3.3.5. Cell Culture and Treatment Protocol 
RAW 264.7 macrophage cells were cultured in DMEM containing 10% (v/v) FBS, L-
glutamine (2 mM), penicillin (50 IU mL–1), and streptomycin (0.3 mg mL–1). The cells were 
maintained in a humidified environment at 37°C and 5% CO2 and cultured in 25 mL polystyrene 
culture flasks. Cells were passaged every 2–3 days at approximately 90% confluence to avoid 
overgrowth. On the day of the experiment, cells were harvested, counted, and plated at the density 




37 °C and 5% CO2. Once the cells adhered to the flask surface they were immediately stimulated 
with LPS (100 ng/mL) and INF-γ (600 U/mL). After 4 h of stimulation, carnosine (at a final 
concentration of 20 mM) was added to the cell medium, and the cells were left to incubate for an 
additional 20 h. For the control experiments, RAW 264.7 cells from the same population were 
incubated with only 20 mM carnosine (no preincubaton with stimulation agents). Additionally, 
untreated (native) RAW 264.7 cells were analyzed to estimate the basal carnosine concentration. 
At the end of incubation the cells were harvested using a cell scraper, and the cell suspension was 
transferred to a centrifuge tube (15 mL). A 100 μL aliquot of the solution containing macrophage 
cells was taken out and cells counted. The cells were then centrifuged at 1137 × g for 4 min at 4°C. 
After centrifugation, the supernatant was removed and the cell pellet was washed twice using cold 
0.01 M PBS at pH 7.4. Next, cell pellets were lysed using 300 µL of 10 mM boric acid and 0.5 % 
Triton X-100 at pH 9.2. The lysate solution was filtered by centrifugation at 18690 × g for 10 min 
in centrifuge tubes equipped with 3 kDa cut-off filters. The filtered lysates were then ready for the 
NDA/CN derivatization procedure. Prior to ME-LIF analysis, each sample lysate (except the 
native one) was diluted by a factor of 20 in BGE. A schematic of this process is shown in Figure 
3.3. 
Cell viability was measured using a Tryphan blue exclusion assay and cell count using a 
C-chip disposable hemocytometer (Bulldog Bio, Inc., Portsmouth, NH, USA). The RAW264.7 
cell suspension was diluted at a 1:1 and 1:3 ratio with 0.4% Trypan blue solution. The number of 
viable cells and cell density were determined using a 4 mm2 total area hemocytometer. Native cells 
typically had densities of about 6 million cells in a 25 cm2 flask. Cell images were obtained using 
an Accu-Scope microscope (Mel Sobel Microscopes Ltd, Hicksville, NY, USA) with 










3.3.6. Fabrication of Glass-Glass Microfluidic Devices 
Glass has many ideal properties as a microfluidic substrate, such as its optical clarity, its 
surface chemistry, its ability to withstand high voltages, and its similarity to fused-silica capillaries  
used for traditional electrophoresis [41]. The fabrication of these devices requires access to a clean 
room facility and a variety of specialized equipment. This includes an UV Flood Source and Mask 
Alignment System (ABM, Scotts Valley, CA), a PDC-32G Plasma Cleaner (Harrick Plasma, 
Ithaca, NY), a BD-20AC Laboratory Corona Treater (Electro-Technic Products, Chicago, IL), an 
Alpha-Step 200 Profilometer (KLA Tencor, Milpitas, CA), and a Scientific Muffle Furnace 
(Fisher, Wlatham, MA). 
A schematic of the glass-glass microfluidic device construction process is shown in Figure 
3.4. The microchannels are fabricated on a glass substrate spin-coated with a layer of chrome and 
positive photoresist (obtained from Telic, Valencia, CA). Briefly, a mask with the desired channel 
geometry is printed using drafting software to create a photomask, which is aligned on the substrate 
and exposed to UV light. This will cause the degradation of the exposed photoresist, which will 
allow it to be removed with developer. The exposed chrome can then be removed via chrome 
etchant, leaving the desired channel design on the glass substrate. Buffer reservoirs are then drilled 
into the substrate using a diamond drill bit (Ukam Industrial Superhard Tools, Valencia, CA). 
Placing the substrate in a bath of hydrofluoric acid will etch the channels to the appropriate depth, 
which should then be confirmed via a profilometer. The remaining photoresist and chrome can 
then be removed with acetone and chrome etchant, respectively. The etched substrate was then 
activated by exposure to oxygen plasma and thermally bonded to a piece of unmodified glass in 
order to create the complete microfluidic device [42, 43]. This fabrication process is explained in 




(A) Align photomask on positive photoresist coated glass substrate and expose to UV light; (B) 
Remove photomask and soak in developer to remove exposed photoresist; (C) Remove exposed 
chrome using chrome etchant; (D) Etch exposed glass with hydrofluoric acid, then confirm 
channel depth with profilometer and drill reservoirs; (E) Remove remaining photoresist with 
acetone (F) Remove remaining chrome with chrome etchant (G) Activate surface via plasma 
exposure and thermally bond to unmodified glass to form complete device. 
  





3.3.7. Microchip Electrophoresis with Laser Excitation Source 
For these experiments, a 15-cm serpentine separation channel was used, with 3-cm side 
channels and a 1.5-cm injection channel. A profilometer was used to confirm the microchannels 
were approximately 17 µm deep and 70 µm wide. Prior to use the microchip was sequentially 
conditioned with 0.1 M HCl, deionized H2O, 0.1 M NaOH, and deionized H2O again via the 
application of a negative pressure using a vacuum system. The channels were then completely 
filled with BGE in the same manner. 
Separations were performed in normal polarity with a high voltage power supply 
(Ultravolt, Ronkonkoma, NY, USA) controlled by software written in Labview (National 
Instruments, Austin, TX, USA). To separate the derivatized amines, 10 kV was applied to the 
buffer reservoir and 7 kV to the sample reservoir, resulting in a field strength of 420 V/cm. Under 
these conditions the separation took 150 s to complete. Electrokinetic injections were employed 
by floating the buffer reservoir voltage for 0.5 seconds to produce the sample plug, as previously 
shown in Figure 1.9.  
The benchtop laser system used for excitation consisted of a 445-nm PhoxX diode laser 
(Market Tech, Scotts Valley, CA, USA) coupled to an Eclipse Ti-U inverted microscope (Nikon 
Instruments Inc., Melville, NY, USA) with a fiber optics cable. The emission light was filtered 
through a long-pass edge filter with a 480 nm cutoff before being focused onto a photomultiplier 
tube (Hammatsu Corporation, Bridgewater, NJ, USA). The data was amplified and filtered before 





3.4.  Discussion 
3.4.1. Microchip Electrophoresis Separation 
NDA/CN derivatization is non-specific and will react with any primary amines present in 
the cell lysate samples. A ME separation was optimized to guarantee that the carnosine peak did 
not co-migrate with any of the most abundant amino acids present in macrophages, as reported in 
the literature [44]. Using a 15-cm separation channel, 20 mM sodium borate BGE (pH 9.2), and 
field strength of 420 V/cm led to a separation that achieved this, as shown in Figure 3.5. The 
system displayed good linearity for carnosine from 65 nM to 50 µM, with a correlation coefficient 
(R2) of 0.994 and an experimental LOD of 65 nM for carnosine (S/N = 3). The migration time of 
the CBI-carnosine peak exhibited an intraday relative standard deviation of 3.55%. 
3.4.2. Quantification of Carnosine in Native Cell Lysate 
When running cell lysate samples on the ME system, it was noticed that there was a shift 
in the migration time of all species compared to the standards prepared in BGE. This was 
determined to be due to the difference in the sample matrix conductivity, as the cell lysate was 
prepared in PBS and had a much higher conductivity. Previous findings in the literature have found 
that sample plugs with higher conductivity (compared to the BGE) will result in longer 
electrophoretic migration times [45]. The separation in cell lysate samples is shown in Figure 3.6, 
demonstrating the shift in migration time in a real sample. 
In order to confirm the identity of the carnosine peak, a standard addition calibration curve 
was performed in the cell lysate samples, as described in the Methods section. The standard 
addition of response vs. the carnosine concentration yielded a R2 value of 0.997, as shown in Figure 





As the NDA/CN reaction will react with any primary amine, the microchip electrophoresis (ME) 
separation needed to resolve carnosine from other present species. (1) carnosine; (2) glutamine, 









Electrophoretic separation of untreated RAW 264.7 macrophage cells, with the carnosine peak 
indicated. Spiking studies were done to confirm its identity due to a shift in migration times 
resulting from differences in the sample matrix. The other peaks that change in the spiked cell 
lysate are believed to be degradation products and did not respond linearly to the carnosine 
spikes. 
  





y = 0.2429x + 0.3861; R2 = 0.9972. 
  





per million native cells could be determined at a concentration of 0.08 (± 0.02) nmol per 106 cells. 
As macrophage cells are the first ones to respond to inflammation processes such as oxidative 
stress, the endogenous presence of carnosine could relate to its antioxidant properties and ability 
to scavenge RNOS. 
3.4.3. Carnosine Uptake in Stimulated Macrophages 
The variation in carnosine uptake between physiological and pro-inflammatory conditions 
could provide a better understanding of its role as an antioxidant during macrophage activation. In 
order to simulate pro-oxidative conditions in vitro, RAW 264.7 macrophage cells were incubated 
in LPS and INF-γ four hours prior to incubation with carnosine. When placed in cell medium, 
carnosine is naturally taken up. The control group consisted of cells that were incubated with only 
carnosine (at 20 mM), while the experimental group was first perturbed with LPS and INF-γ prior 
to incubation with carnosine (at the same concentration). Morphological changes were observed 
in the macrophage cells exposed to LPS that are consistent with inflammatory conditions, as shown 
in Figure 3.8. 
There was a large difference in the degree of carnosine uptake between the two groups, 
which was calculated by dividing the measured carnosine concentration by the number of cells in 
each bulk cell sample. The unstimulated cells had a final intracellular carnosine concentration of 
46.67 (± 8.61) nmol per 106 cells, while the stimulated cells had a drastically higher amount at 
132.41 (± 12.22) nmol per 106 cells, a statistically significant difference (p < 0.001). This is a 2.83 
(± 0.29) factor increase in carnosine uptake between the two experimental conditions.  
The exact mechanism and reason behind the increased uptake of carnosine in stimulated 





Native cells were incubated with carnosine alone and exhibited no morphological changes. 
Stimulated cells were treated with LPS and INF-γ prior to incubation with carnosine and 
demonstrated observable changes in cell morphology. 
  





that these cells, which are integral to the immune response, actively take up antioxidant molecules 
in response to inflammatory stimuli. It is also possible that the use of LPS and INF-γ impact 
membrane permeability, leading to a passive increase in carnosine uptake. Further studies need to 
be conducted to study these macrophage cells following M1 activation to investigate whether this 
is the case via the use of dyes that can detect damage to the cell membrane. 
3.5.  Conclusion 
A ME-fluorescence method was developed for the separation and detection of carnosine in 
bulk cell lysate using the NDA/CN derivatization. Standard addition was used to confirm that 
macrophages contain a low basal intracellular concentration of carnosine. Not only do these cells 
readily take up carnosine present in cell medium, there is also an approximately 3-fold increase in 
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Advances in the Development of an On-line Microdialysis-Microchip System for 
Monitoring Glutamate after Severe Traumatic Brain Injuries 
4.1.  Traumatic Brain Injury 
Traumatic brain injury (TBI) is the most common type of neurotrauma worldwide. In the 
United States alone there are over a million patients admitted to emergency departments with TBIs 
annually [1]. Additionally, it’s estimated that 1% of the country’s population lives with long-term 
disabilities following a TBI [2]. The initial injury can be the result of direct blunt-force trauma, 
acceleration, deceleration, or rotational forces, and is most often caused by falling injuries or 
automobile accidents [3]. This condition has also received a large amount of media attention due 
to its prevalence amongst sports players and veterans returning from active combat zones. 
A mild TBI, commonly referred to as a concussion, is much more common than severe 
injuries. However, many patients who suffer from concussions do not receive immediate medical 
treatment, making it difficult to estimate the exact number of cases annually [4]. The clinical 
severity of a TBI is determined by medical personnel by using the Glasgow coma scale (GCS), a 
practical method of determining the level of consciousness following head injuries, as shown in  
Table 4.1 [5]. Although there is some evidence that suggests the GCS can predict long-term 
outcome after suffering a TBI, it does not examine any neurochemical indicators of short- or long-
term damage [6]. 
If a patient has a score of less than 8 on the GCS, they are considered comatose and have 
suffered from a severe TBI. This usually necessitates a surgical procedure to reduce intracranial 





Table 4.1: The Glasgow Come Scale, a clinical method of measuring the severity of TBI  
patients, with a best possible score of 15. Patients are considered comatose with a score of less 










Eye opening response 
 
• Spontaneously 
• To speech 
• To pain 






Best verbal response 
 
• Oriented and self-aware 
• Confused 
• Inappropriate words 
• Incomprehensible sounds 







Best motor response 
 
• Obeys commands 
• Moves in response to localized pain 
• Flexion withdrawal from pain 
• Abnormal flexion 
• Abnormal extension 












skull, which also gives medical professionals access to the brain in order to monitor neurochemical 
indicators of short-or long-term damage. There has been a growing interest in using microdialysis 
sampling to monitor the neurotransmitters levels (and other indicators of brain health) following a 
severe TBI [8]. 
4.1.1. Severe Traumatic Brain Injury: Primary vs. Secondary Damage 
When examining a TBI, the damage done to the brain can be broadly split into two 
categories. Primary damage is the result of the direct mechanical damage caused by an external 
force. This results in skull fractures, white-matter shearing, hematomas, blood vessel tears, focal 
contusions, and diffuse swelling. TBI patients can be separated into three categories depending on 
the degree of primary damage suffered: acute subdural hematoma (SDH) TBIs, diffuse axonal 
injury (DAI) TBIs, and contusion TBIs [9]. There is very little that can be done by medical 
professionals to limit primary damage, as it has already occurred before the patient receives 
emergency care. 
 However, the initial trauma can also initiate pathophysiological pathways that lead 
to additional brain damage, which is referred to as secondary damage. Some of the mechanisms 
that link primary and secondary damage are shown in Figure 4.1 [10]. The secondary damage itself 
is the result of inflammation [11], receptor-mediated damage [12], calcium-mediated damage [3], 
and oxidative stress [13]. The category of TBI determines which of these pathophysiological 
pathways results in the most secondary damage, as shown in Figure 4.2. 
As secondary damage develop in the hours and days after the initial trauma event, medical 
professionals usually have the opportunity to monitor and treat these pathophysiological pathways. 
However, they require methods that will allow them to monitor the levels of biomolecules related 




The initial trauma event directly causes primary damage, which in turn leads to secondary 
damage. The central gray loop is known as the vasodilatory cascade [10]. 
 
  





The amount of contribution of different type of secondary damage depends on the type of 
primary damage associated with a TBI [9]. 
  





4.1.2. Excitatory Amino Acids and Secondary Damage 
It is widely acknowledged that the excitatory amino acid (EAA) neurotransmitter glutamate 
plays a pivotal role in the secondary damage following a TBI. The initial trauma produced will 
lead to increased production of EAA neurotransmitters. This excessive glutamate will cause 
depolarization of the cell membrane in nearby neurons, leading to the breakdown of ion channels 
that will consequently release more glutamate into the extracellular fluid (ECF) and lead to the 
depolarization of additional neurons. This will result in a phenomenon known as spreading 
depolarization, which damages the ability of neurons to propagate an action potential and leads to 
neuronal swelling and dendritic distortion [14]. Glutamate is also highly cytotoxic and can directly 
result in neurotoxicity when it overcomes the ability of transporters that would normally maintain 
safe levels in the ECF [15]. Excessive levels of glutamate will also open the gates of Ca2+ ion 
channels, leading to an influx of calcium ions that results in apoptosis [16, 17]. Additionally, 
excess levels of glutamate will result in mitochondrial dysfunction, which will produce the RNOS 
superoxide and lead to oxidative stress.  
This pathophysiological pathway is collectively referred to as excitotoxicity due to the fact 
it is associated with excitatory neurotransmitters. Glutamate is not the only EAA that has proven 
to be highly deleterious in regards to secondary damage following a TBI [18, 19]. A simplified 
schematic of the mechanisms of EAA-driven damage in a neuron cell following TBI are shown in 
Figure 4.3. There has been a large degree of interest in being able to monitor these compounds in 
vivo using microdialysis sampling to assist medical professionals in determining the timing of 











4.1.3. Limitations of Biosensors for EAA Detection 
Using biosensors for the detection of glutamate is by no means novel and has previously 
been previously reviewed [20]. Biosensors possess a biorecognition element that can generate 
electroactive species from glutamate to allow amperometric detection. Two enzymes used for this 
purpose are glutamate oxidase [21] and glutamate dehydrogenase [22]. In the former’s case, the 
enzyme catalyzes a one-step redox reaction to consume O2 and produce H2O2, either of which can 
then be directly detected on the electrode. These biosensors demonstrate excellent spatial 
resolution (10 – 20 µm) [20], but their design does not allow for the detection of multiple analytes 
simultaneously. Measuring the concentration of multiple amino acids in the brain would therefore 
require multiple sensors, complicating the overall system. Although electrochemical sensors for 
glutamate have been studied the most extensively, a biosensor for aspartate that uses aspartate 
aminotransferase as the biorecognition agent has also been reported in the literature [23]. 
4.1.4. Microdialysis Sampling 
Microdialysis (MD) is a diffusion-based technique that allows for continuous sampling of 
an in vivo environment. A MD probe with a semi-permeable membrane is surgically implanted in 
the tissue of choice. A solution matching the in vivo environment, known as the perfusate, is flowed 
through the probe at low flow rates. Any analyte below the molecular weight cut-off (MWCO) of 
the semi-permeable membrane will diffuse across it and be collected in the final solution, which 
is referred to as the dialysate, as shown in Figure 4.4 [24]. This provides a continuous sampling 
technique that is clean of macromolecules (such as proteins) that might otherwise complicate 
analysis. The extraction efficiency of the analytes is directly dependent on the flow rate of the 





In this design, a semi-permeable membrane (PAN) attaches two lengths of polyimide tubing. 
Analytes below the molecular weight cut-off (MWCO) of PAN can diffuse across the membrane 
to be collected in the dialysate. The length of the membrane can be modified depending on the 
tissue site of interest and surgical requirements. 
  





The extraction efficiency of analytes through a microdialysis probe is directly dependent on the 
flow rate of the perfusate, which impacts the sample volume collected. For the setup on the left, 
the perfusate is at a flow rate of 1 µL/min, which allows for a large volume of sample to be 
collected; however, a lower amount of analyte will diffuses across the membrane. For the setup 
on the right, higher concentrations of analyte are collected, but in a much smaller sample volume 
over the same time period due to the lower flow rate (100 nL/min). 
  





Techniques that require larger sample volumes will either impact the extraction efficiency or 
temporal resolution of MD sampling. The extraction efficiency (EE) of an analyte across the 




  (5) 
Here, Cs is the concentration in the sample (brain ECF), Cp is the concentration in the 
perfusate, and Cd is the concentration in the final dialysate. In experiments where the analyte is 
not incorporated in the perfusate, the Cp value is zero, while the goal is to determine Cs. This 
simplifies the equation and allows for the experimental determination of the overall relative 




 × 100 (6) 
As previously mentioned, MD sampling is often used to monitor the health of patients 
following a severe TBI in a medical setting [8]. Since these patients already require a section of 
their skull to be removed to relieve intracranial pressure, a MD probe can be surgically implanted 
in the brain tissue during the operation.  
4.1.5. Monitoring Biomarkers of TBI with Microdialysis 
The limitations of EAA biosensors has led to the development of several other methods to 
detect small molecules indicative of brain health and damage. Research by Martin Boutelle and 
colleagues has been instrumental in this field and they have used a wide range of equipment to 
monitor human patients after undergoing a decompressive craniectomy. They have incorporated 
strip electrodes to measure electrical activity and track spreading depolarizations [27], as well as 
developing microfluidic chambers that allow the detection of glucose, lactate, and potassium ions 
within a microdialysis sample using microelectrodes [28, 29]. These are all important markers of 




combination with monitoring blood flow, they were able to combine this information in order to 
measure a chemical signature of spreading depolarizations in vivo [29]. However, their work has 
not yet focused on the detection of EAAs using these techniques. 
Microchip electrophoresis (ME) was previously discussed in Chapter 1 and has been used 
extensively for the detection of amino acids, usually with fluorescence detection. Some examples 
of common fluorescent reagents used for this purpose were shown in Table 1.2. Some of the 
earliest studies using ME for the detection of amino acids reported separations that occurred within 
15 seconds and boasted improved limits of detection due to sample stacking [30]. Additional 
studies using indirect fluorescence allowed for the separation of nineteen amino acids within two 
minutes [31]. Both of these studies were in vitro and were not focused towards working with 
biological sampling methods.  
Microdialysis sampling (MD) coupled to microchip electrophoresis has recently grown as 
a subject of interest for analyses such as this, combining the continuous sampling of MD with the 
fast separations and small solvent requirements of ME, as has recently been reviewed in the 
literature [32]. The small sample size necessitated by the concentration-driven diffusion of the 
analytes in MD sampling is not a limitation for ME, which injects much smaller sample volumes 
than techniques like liquid chromatography [32]. Companies such as CMA Microdialysis produce 
standardized MD probes, syringe pumps, tubing, and other equipment for use by researchers and 
medical professionals. 
Robert Kennedy published work using OPA and NDA derivatization (see Table 1.2 and 
Figure 1.5), along with various MD-ME designs, in order to track the change of glutamate and 
aspartate in vivo following the introduction of a glutamate transport inhibitor [33, 34]. Additional 




monitoring with microdialysis sampling using NDA [35]. The design of the microchip geometry 
was further improved to improve the on-line derivatization reaction and achieve better limits of 
detection [36]. 
4.2.  Methods 
4.2.1. Materials and Reagents 
Sodium cyanide (NaCN), acetone, isopropyl alcohol, polyethylene tubing (I.D. 0.39 mm, 
O.D. 1.09 mm) and parafilm were all purchased from Fisher (Waltham, MA). SU-8 photoresist 
and developer were purchased from Microchem Corp (Flanders, MA). Sodium chloride (NaCl), 
potassium chloride (KCl), calcium chloride (CaCl2), magnesium chloride (MgCl2), sodium 
phosphate dibasic anhydrous (Na2HPO4), sodium phosphate monobasic (Na2H2PO4), glutamate, 
aspartate, and L-cysteic acid were purchased from Sigma-Aldrich (St. Lous, MO). Silicone wafers 
(100-mm thickness) were obtained from University Wafer (Boston, MA). SylgardTM Silicone 
Elastomer Base and Curing Agent were both purchased from Dow Corning (Auburn, MI). A 
syringe pump designed for microdialysis (Model CMA 100) and appropriately sized syringes were 
obtained from CMA Microdialysis (Holliston, MA). Various port connecters with low dead 
volumes were obtained from Labsmith (Livermore, CA). 
4.2.2. Fabrication of PDMS-Glass Microfluidic Devices 
Microfluidic devices constructed using polymeric substrates have grown popular due to 
their shorter fabrication times compared to the all-glass devices described in Chapter 3, which 
makes them better suited for prototyping or other studies were rapid throughput is necessary. 
Polydimethylsiloxane (PDMS) is by far the most common polymer used due to its elastomeric 
properties, optical transparency, and low cost [37]. Combining the benefits of fabricating 




of hybrid devices using both materials [38]. This fabrication process still requires a clean room 
facility and the specialized equipment listed in Chapter 3 for glass-glass microchip fabrication, 
along with a Cee 200CBX Spin Coater (Brewer Science, Rolla, MO). 
A schematic showing the fabrication microfluidic channels in PDMS is shown in Figure 
4.6. Briefly, a silicon wafer is spin-coated with negative photoresist (such as SU-8) at the desired 
thickness. A photomask with the desired channel geometries is aligned on the wafer and exposed 
to UV light. This will cause the photoresist to polymerize. Unexposed photoresist can be removed 
with developer, at which point the wafer is baked to harden the remaining microfeatures. This 
silicon wafer can now be used to create multiple PDMS devices by pouring on elastomer and 
curing agent and allowing it to cure for at least two hours. After curing the PDMS can be peeled 
off of the master when needed and can be reversibly or irreversibly bound to another substrate to 
create the complete device. When coupling with MD, which includes a pressure-driven flow, it is 
necessary to irreversibly bind the PDMS to avoid delamination [32]. This is done by oxidizing the 
PDMS surface with a handheld plasma oxidizer and firmly pressing it to the substrate [37, 39]. 
This fabrication process is explained in further detail in Appendix 2. 
4.2.3. NDA/CN Derivatization and Internal Standard Selection 
The NDA/CN derivatization reaction was previously discussed in Chapters 1 and 3. 
Naphthalene-2,3-dicarboxaldehyde (NDA) is a fluorgenic reagent designed for derivatizing 
primary amines, such as EAAs, to form highly-fluorescent CBI derivatives, as shown in Figure 
1.5 [40].  
Due to the fact this will be an online device, it was desired that the derivatization reaction 





(A) Spin coat a substrate, such as a silicon wafer, with negative photoresist; (B) Align photomask 
on coated substrate and expose to UV light; (C) Remove photomask and soak in developer to 
remove non-polymerized photoresist to create the master, then confirm channel dimensions with 
profilometer; (D) Pour PDMS and elastomer at desired ratio on master, then cure for at least two 
hours; (E) Peel off PDMS with microchannels intact; (F) Reversibly or irreversibly bond PDMS 
to desired substrate to form complete device. 
  





reaction was proceeding, an internal standard was incorporated into the derivatization reaction. L-
cysteic acid has long been used as an internal standard for amino acid analysis [41] and has been 
previously shown to have no role in the biochemistry of NMDA-receptors [42]. It is structurally 
similar to the EAAs of interest (as shown in Figure 4.7), which should result in similar separation 
efficiencies and quantum yield, yet was not detected in brain microdialysis samples using an 
analytical method with a LOD of 356 pM [43]. Its low endogenous concentrations and similarity 
to the analytes of interest makes it a suitable internal standard for this study. 
NDA was prepared at a concentration of 5 mM in ACN. NaCN was prepared at a 
concentration of 20 mM in BGE. L-cysteic acid was then prepared in the NaCN solution at a 
concentration of 75 µM in the NaCN solution. When combined in a 1:1:1 flow rate with NDA and 
the MD flow, this should result in a final derivatized concentration of 25 µM for L-cysteic acid. 
4.2.4. Linear MD Probe Fabrication 
Although the eventual goal of this system is to use intracranial microdialysis probes, these 
probe designs result in higher backpressures. For this reason, a linear microdialysis probe was 
fabricated and used for these in vitro studies, as was shown in Figure 4.4. Polyacrylonitrile (PAN) 
membrane with a MWCO of 20 kDa from Hospal (Lakewood, CA) was used as the semi-
permeable membrane. This membrane had an outer dimension (OD) of 350 µm and an inner 
dimension (ID) of 260 µm. The membrane was attached with UV glue to two lengths of polyimide 
tubing (160 µm OD, 120 µm ID). The probe window was 10 mm long. 
 Since MD sampling is based on diffusion, the perfusate solution needs to mimic the 
extracellular fluid as closely as possible. Artificial cerebrospinal fluid (aCSF) has been developed 





At physiological pH (7.4), glutamic acid and aspartic acid are have a net charge of -1 and 
function as EAA neurotransmitters. The similarities in their size/structure (i.e. hydrodynamic 
radius) and charge states makes L-cysteic acid a good internal standard candidate [41]. 
  





studies was 125 mM NaCl, 2.7 mM KCl, 1.2 mM CaCl2, 1 mM MgCl2, 2.3 mM Na2HPO4, and  
0.45 mM Na2H2PO4, prepared in H2O. 
4.2.5. Microchip Electrophoresis with Laser Excitation Source 
These experiments were performed using a double-T microchip design with a 15-cm 
separation channel. This particular design has a wider inlet channel to accommodate the pressure-
driven flow coming from the MD probe and syringe pump. This channel was connected to the MD 
tubing via a steel pin pushed through the PDMS to reach the inlet. Prior to use the microchip was 
conditioned with 0.1 M NaOH and deionized H2O before being filled with BGE via the application 
of a negative pressure using a vacuum system. After piercing the PDMS with the steel pin, BGE 
was also pushed through the inlet with a syringe to fully fill the inlet channel and guarantee that 
no de-lamination occurred. 
The setup of the high voltage power supplies, benchtop laser system, and data acquisition 
were previously described in Chapter 3. The BGE and voltages applied for the separation were 
experimentally determined and are discussed later. An electrokinetic injection was accomplished 
by floating the separation voltage for 0.5 s to produce a sample plug, as previously shown in Figure 
1.9. 
4.3.  Discussion 
4.3.1. Online MD-ME System Design 
The syringe pump was set up with three syringes connected with polyethylene tubing. The 
first syringe contained the NDA solution, while the second contained the NaCN solution with the 
internal standard. These two syringes were connected directly to a low-volume mixing tee by 5 cm 












the fabricated linear MD probe with PAN membrane before being connected to the same mixing 
tee. The output from the mixing tee was then connected to the MD inlet on the PDMS-glass hybrid 
microchip, as shown in Figure 4.8. 
4.3.2. ME Separation of EAAs with Offline Derivatization 
The ME separation conditions were optimized using an in vitro setup in which a mix of the 
EAAs and internal standard were derivatized off-line, then placed in a syringe and flowed through 
the microdialysis inlet on the microfluidic device. In order to guarantee full derivatization, this 
reaction was allowed to proceed for 45 minutes in the dark before the CBI products were placed 
in the syringe. This eliminated any issues stemming from the incomplete reaction that would lower 
the signal response and complicate the analysis. As borate buffers have been extensively used for 
EAA analysis in the past [35, 36, 44, 45], it was decided that such a buffer would be well-suited 
for this system. 
BGE was prepared by making boric acid (pKa = 9.24) solutions at three concentrations (20, 
50, and 80 mM) and adjusting the pH to 9.2 using 0.1 M NaOH in order to generate a buffer. As 
electrophoretic separations are also highly dependent on the applied voltages and corresponding 
field strengths (as discussed in Chapter 1), high- and low-field strength conditions were examined. 
The results of these experiments are shown in Figure 4.9. It was determined that a BGE of 50 mM 
borate (at pH 9.2) and a field strength of 224 V/cm provided ample resolution between the two 
EAAs of interest and the internal standard. 
4.3.3. EAA Separation with MD Sampling and On-line Derivatization 
After optimizing the separation conditions, two of the syringes were filled with the 





The final conditions were a BGE consisting of 50 mM borate (pH 9.2) and a field strength of 
344 V/cm. (1) glutamate; (2) aspartate; (3) L-cysteic acid. This was the fastest separation in 
which all three of the analytes were fully resolved. 
  





linear MD probe, which was placed in a solution containing glutamate and aspartate at a 
concentration of 200 µM in aCSF. The syringe pump was used to push solutions at 1 µL/min 
through each syringe. The length of tubing where the derivatization occurred (at a combined flow 
rate of 3 µL/min) was 10 cm long (internal volume of approximately 16 µL), resulting in a 
derivatization time of approximately five minutes before reaching the inlet channel. The overall 
lag time from the MD probe suspended in the EAA solution to the inlet was approximately 12 
minutes (including the derivatization time), although this could be lowered by increasing the flow 
rate of the syringe pump. 
The on-line derivatization system was run for over 30 minutes, over which time the 
background current remained stable. Although no peak for the EAAs was originally present, the 
internal standard was clearly visible from the first injection at a time of 86 s, suggesting that the 
derivatization reaction was proceeding correctly. Over the course of the experiment, small peaks 
that co-migrated with glutamate and aspartate developed within individual injections (as shown in 
Figure 4.10). Unfortunately, they were never detected above the LOD of the system, with a signal-
to-noise ratio (S/N) of approximately 2.  
This suggests that the on-line derivatization setup is viable, but further optimization would 
be necessary before it could be used in vivo. This is especially true because the in vivo 
concentrations of EAAs in the brain are much lower than in this in vitro experiment (as low as 
0.28 µM for basal glutamate) [46].  
It was hypothesized that the difference in the height of the internal standard peak compared 
to that of the analytes was due to their diffusion across the MD membrane. Previous work has 





Although glutamate (1) and aspartate (3) peaks are present in the correct migration order before 
the internal standard peak (3), they are below the LOD of the system, with an S/N of 
approximately 2. 
  





analytes across it (beyond its MWCO value) [47]. The extraction efficiency and relative recovery 
of these EAAs across the PAN membrane was not experimentally determined, but it is possible 
that other commercially-available membrane materials such as poly(ether) sulfone, polycarbonate, 
or cuprophan could provide for better analyte recovery. When moving to in vivo experiments, the 
biofouling of the membrane from tissue effects will also need to be considered and evaluated [48]. 
4.4.  Conclusion 
A microdialysis-microchip electrophoresis system with on-line derivatization was 
developed and optimized for the sepration and detection of excitatory amino acids following a 
traumatic brain injury. The EAAs were derivatized via the NDA/CN reaction. L-cysteic acid 
functioned as an internal standard and guaranteed that there were no mechanical issues in the 
overall system. There was a lag time of approximately 12 minutes between the MD probe and the 
electrokinetic injection onto the ME system, which included the on-line derivatization reaction. 
Although the presence of a reproducible internal standard peak demonstrated that the overall 
system was functional in vitro, it did not possess sufficient LODs for in vivo analysis due to the 
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Conclusions and Future Directions 
5.1.  Conclusions 
In this thesis, the development of analytical methods to fluorescently derivatize and detect 
small molecule biomarkers that are of pivotal information to epilepsy, the immune response, and 
traumatic brain injury was described.  
A liquid chromatography-fluorescence method was developed that allowed for the 
detection of three reactive aldehyde biomarkers of lipid peroxidation: 4-hydroxynonenal, 
malondaldehyde, and acrolein. Previous research has shown that secondary damage following an 
epileptic seizure can lead to oxidative damage, which should be reflected by a change in 
concentration of these compounds. This method had sufficient limits of detection (6.1 nM for 
HNE, 192 nM for MDA, and 2.6 µM for acrolein) to measure all three analytes at endogenous 
levels in rat urine samples after derivatization with DNSH and pre-concentration using solid phase 
extraction. When combined with an animal model of epilepsy, acrolein demonstrated a statistically 
significant increase in the first 12-hour period following the seizure, while 4-HNE had no 
noticeable change. These aldehydes also displayed a previously unreported circadian cycling 
according to the light/dark cycle of the animal. 
A microchip electrophoresis-fluorescence method was developed in order to detect 
carnosine in macrophages, the primary cells activated during the immune response. This method 
yielded a LOD of 65 nM and was linear over three orders of magnitude at physiologically relevant 
concentrations (50 nM – 50 µM). Native cell lysate was derivatized using the NDA/CN reaction 
to detect the endogenous level of carnosine, which was found to be 0.079 ± 0.02 nmol per 106 




uptake of carnosine into macrophages was also examined under normal and pro-oxidative 
conditions by stimulating the cells with LPS and INF-γ. There was a 2.83 ± 0.29 increase in uptake 
for the stimulated cells, suggesting that they will actively take up this dipeptide in order to mitigate 
the damage caused by pro-oxidative inflammation. 
A second microchip electrophoresis-fluorescence system was developed to measure 
excitatory amino acids involved in neuronal damage in traumatic brain injury. The system was 
designed for used in a medical setting with minimal delay between sampling and analysis. 
Microdialysis sampling was coupled with on-line derivatization with a lag time of 12 minutes 
between the microdialysis probe and sample injection. L-cysteic acid was incorporated as an 
internal standard to guarantee the NDA/CN reaction was functioning and that no issues developed 
throughout the entire system. Although the overall system functioned for several sequential runs, 
a lack of response for the EAAs suggests that further optimization of the probe membrane and 
analyte recovery is necessary before this can be used as a monitoring tool. 
5.2.  Future Directions 
5.2.1. Reactive Aldehyde Biomarkers of Lipid Peroxidation 
Although a method was developed to detect reactive aldehydes in urine samples, being able 
to measure their concentrations in the brain with better temporal resolution would provide more 
relevant information to develop new therapies for epilepsy. Although brain microdialysis sampling 
has been used to study various biomarkers of epilepsy, the only reactive aldehyde to receive a 
strenuous examination using this sampling technique in vivo is MDA [1]. Using a similar animal 
model but studying more biomarkers of lipid peroxidation could provide a better understanding of 




Another benefit of microdialysis sampling when it comes to in vivo epilepsy experiments 
is that it can be used to dose a specific region of the brain with the convulsing agent, producing 
local seizures [2]. A series of experiments investigating the output of reactive aldehyde species 
following local seizures could reveal if there is any change in the response depending on the 
associated region of the brain. Differences in neurochemical concentrations following epileptic-
like seizures have been previously reported [3], which was later linked to differences in brain 
region activity. This suggests that a similar study would prove necessary regarding reactive 
aldehyde species. 
5.2.2. Antioxidant Properties of Carnosine in Macrophages 
The exact role of carnosine in the antioxidant defense system has yet to be elucidated, 
despite the fact it is endogenously present in murine macrophage cells. One way to further explore 
this would be a more thorough examination of inducible nitric oxide synthase activity in these 
cells. This enzyme converts arginine to citrulline in order to produce nitric oxide. This means that 
the ratio of these two amino acids can be used as an indication of iNOS activity [4]. Since they 
will also be derivatized by the NDA/CN reaction, changing the separation conditions in order to 
measure them in addition to carnosine could prove information on whether its antioxidant 
properties come from interfering with the production of NO• by iNOS. Some initial experiments 
have been done in this direction, with the peaks corresponding to citrulline and arginine identified 
and their relative signal response evaluated, as shown in Figure 5.1. In the native macrophage 
lysate, the signal response for citrulline and arginine was nearly equal. However, under pro-
inflammatory conditions, it appears as if there is a larger signal response from citrulline than 
arginine, which corresponds with a higher degree of iNOS activity. Further studies need to be 




Under native conditions, the ratio of the citrulline to arginine signal response is nearly equal; 
under pro-inflammatory (i.e. activated) conditions, there appears to be a high amount of 
citrulline compared to arginine, which would correspond to a larger amount of iNOS activity. 





It has long been known that histidine is one of the amino acids with the strongest 
antioxidant properties [5]. Since this is one of the constituent amino acids of carnosine, it is 
possible that the antioxidant activity of the dipeptide is simply due to its degradation, resulting in 
an increased intracellular concentration of histidine. Since the pKa of histidine’s amine moiety is 
9.17, it has an overall net charge of approximately -1/2 at the pH of this study’s BGE, which 
resulted in it co-migrating with the neutral amino acids. Changing the buffer conditions to a 
different pH (such as using phosphate buffer, which has a pKa of 7.2), would allow for it to be 
more easily separated with electrophoresis and measured following the uptake of carnosine into 
macrophage cells. 
The amount of damage done to the cell membrane could also influence carnosine 
permeability. There are several fluorescent dyes that can indicate cell health following M1 
activation that would be able to identify if this is the cause of increased uptake. 
5.2.3. Excitatory Amino Acids Related to Traumatic Brain Injury 
Although these experiments used a benchtop laser system, work has been done in the 
development of a mobile fluorescence detection platform that couples with microchip devices [6]. 
This portable system uses a light-emitting diode as an excitation source and reported limits of 
detection near the physiological ranges of glutamate and aspartate in the extracellular spaces of 
the brain (1.3 and 1.2 µM, respectively). Combining this portable system with a wholly on-line 
separation would allow for the overall method to be used in a medical setting. 
The current method also used off-chip derivatization, while previous research has been 
conducted using mixing geometries on-chip in order to increase the reaction rate and reduce any 
complications from excessive tubing [7]. Although this device was successful, it still struggled to 




reach completion without ample agitation. The degree of mixing can be further improved by 
optimizing the design of the mixing channels, such as a double helix design that was recently 
discussed in the literature [8]. In order to maximize the throughput of prototyping new 
microchannel geometries, it would be preferable to switch to a substrate that could be prepared 
faster than glass, while providing more reproducible results than PDMS. One such option is cyclic 
olefin copolymer, which has been extensively used for microchip electrophoresis devices and can 
be bonded at room temperature [9]. 
Although a wide range of animal models for TBI exist [10], there has been extensive work 
done on creating in vitro models that limit the number of animals that are exposed to these models, 
which are violent by necessity. Three-dimensional cell cultures have shown promising results in 
this regard, with brain-like matrixes already under development that have demonstrated lifelike 
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Quick Reference to Glass-Glass ME Device Construction 
This appendix will provide step-by-step instructions on the fabrication of glass-glass 
microchip electrophoresis (ME) devices, along with some notes gathered from personal experience 
that might not be reported in the literature. 
Photolithography 
1. Pre-bake glass substrate, photoresist side up, on a hotplate at 100 ºC for 2 minutes. 
Note: The prebake time will vary according to the photoresist type and thickness. 
Consult the photoresist documentation for more information. 
2. Allow glass to cool to room temperature before proceeding. 
3. Place photomask on glass substrate such that the printed side of the photomask is in contact 
with the photoresist. Apply a vacuum to ensure minimal distance between mask and 
photoresist.  
4. While maintaining a vacuum, expose the photoresist to UV through the photomask. 
Duration of exposure will depend on resist type, thickness, and UV intensity. 
5. Place exposed glass substrate in developer to remove exposed area. 
6. Wash with water and dry gently with compressed nitrogen or air. 
7. Place on hotplate at 100 ºC for 10 minutes to fully evaporate developer. 
Chrome Removal 
8. Place wafer in a Pyrex™ dish of chrome etchant. 
9. Agitate gently until chrome regions are clear (wait 45+ seconds after the chrome appears 






10. Rinse with water and dry using compressed nitrogen or air. 
Note:  Chrome and photoresist must be removed from glass before a glass cutter 
will be effective. If making multiple devices simultaneously, it is important to 
include these cut lines in the photomask design. Additionally, chrome-coated glass 
will appear transparent before all chrome has been removed. However, a thin layer 
of chrome that remains will prevent glass-glass bonding. For this reason, allow the 
glass substrate to remain in the chrome etchant for 45 seconds after it appears that 
the chrome has been removed. Additional etching beyond this period will begin to 
undercut features.  
Glass Cutting and Drilling 
11. Using a glass cutter, cut glass along exposed paths between individual devices.  
Note: Extreme care should be taken not to scratch the surface of the photoresist. If 
this is a problem, the glass cutting and drilling steps can be performed after the HF 
wet etching. 
12. Once separated, place individual ME devices in approximately 1 cm of water with a 
sacrificial layer under the chip to allow the drill to pass through without being damaged. 
13. Slowly drill glass, applying constant pressure. It may be necessary to use gradually 
increasing drill bit sizes. 
Note: More ME devices are destroyed in this step than any other. Using new 
diamond-coated bits can help prevent glass breakage. When choosing drill bit sizes, 
two things to consider are whether or not MD access ports will be glued into place 




create sample and buffer wells are too small, these solutions will evaporate rapidly 
during operation. As this evaporation proceeds, ionic strength will change. This in 
turn will cause additional current draw and, consequently, alter migration times. If 
MD access ports are to be placed over the holes, the holes must of course be smaller 
than the ports themselves. 
HF Wet Etching 
14. Place glass with photoresist/chrome side up in HF etchant and agitate for duration of 
etching process. Etching time will depend on desired depth as well as glass type. 
15. Remove from HF etchant, rinse with a solution of calcium acetate to deactivate the HF 
etchant. Following this, rinse with water and dry using compressed nitrogen or air. 
16. Measure channel depth using a profilometer. If the desired depth has not been achieved, 
calculate the etch rate and place the device back in the HF for the necessary amount of 
time.  
Note: Due to the extreme toxicity of HF, the best practice is to minimize the number 
of times the device is taken in and out of the HF etchant if at all possible. When 
handling the substrate, the HF remaining on the device should first be deactivated 
by rinsing with a slurry of calcium acetate in water, followed by rinsing with water.  
Removal of Remaining Photoresist and Chrome 
17. Remove all remaining photoresist by rinsing with acetone. 





19. Place the glass substrate in chrome etchant, agitating gently, until all remaining chrome 
has been removed (wait 45+ seconds after the chrome appears to be gone). 
Note: The removal of all photoresist and chrome is necessary to facilitate a glass-
glass bond. 
Bonding Glass-Glass ME Devices 
20. Cut blank glass to the necessary size. 
Note: To avoid breakage due to differences in thermal expansion, blanks should be 
of the same glass type as the etched device. 
21. Clean both glass pieces using Alconox™ mixed to the manufacturer’s specifications. 
22. Rinse both sides well with deionized water (DI) water 
23. Incubate the glass surfaces to be bonded using a solution of 0.5% (w/v) calcium acetate, 
approximately 30 mM, and 0.5% (w/v) Alconox™ in DI water for no less than 30 seconds. 
24. Rinse thoroughly with DI water. 
25. Under running DI water, bring glass pieces together from bottom to top. 
Note: Force out any remaining bubbles but allow a layer of water to remain. 
26. Place the device in an oven for 1 hour at 60 ºC. 
Note: Do NOT force all water from between the layers. The evaporation from the 
oven will help force the glass together. 
27. At the 1-hour mark, inspect the device for Newton rings indicating incomplete bonding of 
the surfaces. If found, separate using a razor blade and repeat steps 21–26. 
28. Place binding clips around the device to apply additional pressure. Increase the temperature 




29. Inspect device. If Newton rings have formed, separate using a razor blade and repeat steps 
21–28.  
30. If no Newton rings are found, execute the following program, slowly increasing the oven 
temperature to 630 ºC and holding before cooling gradually to room temperature. Steps 
shown in Table 1. 
31. If the ME device is meant to be used online (MD-ME), access ports must be glued to the 
chip to allow the flow from the syringe pump to enter the device. Polyethelene tubing 
connecting the syringe pump can be connected directly to ports glued to the surface of the 
device. To glue ports in place, a strong UV source such as the ELC-450 (Electrolite Corp, 
Bethel, CT) should be used. UV glue (Fisher Scientific, Waltham MA) should be applied 
carefully to the ports while holding them in place.  
Note: Should glue enter the channels, flush with water and methanol until the glue 






Quick Reference to PDMS-Glass ME Device Construction 
This appendix will provide step-by-step instructions on the fabrication of PDMS-glass 
microchip electrophoresis (ME) devices, along with some notes gathered from personal experience 
that might not be reported in the literature. 
Silicon Master Spin-Coating 
1.  Use nitrogen flow to clean surface of silicon wafer. 
2.  Center silicon wafer on spin coater platform. 
3. Pipette 4 mL of SU-8 10 photoresist onto the exact center of wafer and spin coat at 2000 
rpm until fully coated. 
Note: The amount of SU-8 10 photoresist used directly influences its thickness and, 
subsequently, the final depth of the microfeatures. The values stated in these steps 
are for a final thickness of 15 µm with SU-8 10. Values associated with other 
thicknesses and photoresists should be calculated based on manufacturers’ 
specifications.  
4. Prebake silicon wafer at 65 ºC for 2 minutes on hotplate, then increase temperature to  
95 ºC for 5 minutes. 
Note: To avoid breaking the silicon wafer, it is better to start the hotplate at room 
temperature and gradually ramp up to each specified temperature before heating it 







Silicon Master Photomask Alignment and UV Exposure 
5. Align negative photomask on top of wafer on photolithography platform; use vacuum to 
hold substrate and mask in place. 
Note: When using a printed photomask, make sure that the printed side is facing 
down (flush with the substrate). This will prevent any diffusion of light across the 
width of the transparency and avoid unwanted enlargement of the features. Make 
sure the silicon wafer has cooled to room temperature before aligning the 
photomask. 
6. Expose to UV light for 16 seconds. 
Note: Full UV exposure of SU-8 is dependent on the substrate thickness and light 
source intensity. In this case, a flood-source with output intensity of 21 mW/cm2 is 
used. 
Silicon Master Post-Exposure Processing and Profiling  
7. Post bake silicon wafer at 65 ºC for 1 minute on hotplate, then increase temperature to  
95 ºC for 2 minutes. 
8. Place developed wafer in SU-8 developer; gently swirl for 2 minutes to remove un-
developed photoresist. 
9. Remove master from developer; wash with isopropyl alcohol and dry with nitrogen flow. 
Note: Acetone will cause developed SU-8 to dissolve. Only isopropyl alcohol 
should be used for cleaning silicon masters using this photoresist. 
10. Hardback at 200 ºC for 2 hours. 






12. Measure 12 grams total of a 9:1 ratio of Sylgard™ 184 elastomer (10.4 g) and curing agent 
(1.6 g) into a small cup; mix thoroughly.  
Note: This amount of polymer was chosen because the surface tension will be 
sufficient to hold the mixture on the master’s surface. Greater amounts can be used, 
but a mold will be necessary to hold the polymer on the wafer’s surface. Using 12 
g will result in a final thickness of approximately 1.2 mm. 
Note: Different ratios of elastomer to curing agent can be used in order to modify 
the elasticity of the PDMS. In general, the more curing agent used, the less elastic 
is the final polymeric substrate. 
13.  Place cup inside vacuum desiccator and remove all gas bubbles via repeated application of 
vacuum, being careful not to spill polymer over the edges of the container. 
14.  Pour mixture onto master and allow it to settle to a uniform thickness; place in oven and 
heat at 70 ºC for at least two hours. 
Note: Make sure that the master is level once it is placed in the oven. If it is placed 
at an angle, the PDMS will cure unevenly and potentially be unusable. 
15.  Use a razor blade to scrape the PDMS off of the edges of the master, then slowly peel off 
the polymer layer, being careful not to stretch or rip the substrate. 
16.  Either bond immediately (the next two sections detail the process for reversible and 
irreversible bonding) or place the PDMS on a piece of Parafilm™, channel-side down; fold 




Note: If protected from air exposure, PDMS can safely be sealed within Parafilm™ 
for up to one week. If cracks are visible in the microchannels when examined using 
a microscope, the polymer has dried out and should not be used. 
Reversible Bonding to Glass 
17. Use a PDMS hole puncher to remove PDMS at reservoirs and create wells, using a 
Kimwipe to clean the puncher surface between each use. 
 Note: This step is not needed if wells have been drilled in the glass substrate.  
18. Wipe down the glass substrate with a Kimwipe soaked in 50% isopropyl alcohol (IPA), 
then dry with lint-free paper and nitrogen flow. 
19. Peel Parafilm™ off PDMS 
Note: If bonding in a cleanroom facility, there should be no dust or other detritus 
on the substrate surface. A piece of clear tape can be used to remove any particulates 
on both glass and PDMS if necessary. 
20. Slowly place PDMS on glass substrate, channels facing inwards; run fingers over the 
PDMS to force out any air bubbles that form between the layers. 
21. Examine device using a microscope to guarantee the microfeatures are preserved and no 
clogs are present. 
Note: If there is particulate in the channels or improper sealing, the PDMS can be 
peeled off the glass and re-applied after using tape to clean both substrate surfaces. 
Irreversible Bonding to Glass 
22.  Use a PDMS hole puncher to remove PDMS at reservoirs and create wells, using a 
Kimwipe to clean the puncher surface between each use. 




23. Wipe down the glass substrate with a Kimwipe soaked in 50% IPA, then dry with lint-free 
paper and nitrogen flow. 
24. Peel Parafilm™ off PDMS. 
Note: If bonding in a cleanroom facility, there should be no dust or other detritus 
on the substrate surface. A piece of clear tape can be used to remove any particulates 
on both glass and PDMS if necessary. 
25. Run a handheld plasma oxidizer (BD-20AC, Electro-Technic Products, Chicago IL) over 
the surface with the electrode a centimeter above the polymer surface, spending around 30 
seconds on each piece of PDMS 
Note: A conventional plasma oxidizer (Harrick Scientific, Ithaca NY) can also be 
used. It is not recommended to oxidize PDMS for more than 2 minutes, as this can 
result in degradation of the surface and potential damage to any microfeatures or 
improper bonding. 
26. Firmly press the substrates together, taking care to avoid touching the oxidized surface; run 
fingers over the PDMS to force out any air bubbles that form between the layers 
27. Apply pressure with fingertips around the edges of the microchip until sealed, usually 
within one or two minutes. 
Note: Applying pressure directly over the channels can result in forcing them closed 
and ruining the device. 
28. Examine device using a microscope to guarantee that the microfeatures are preserved and 
no clogs are present. 
Note: If there is particulate in the channels or improper sealing, the PDMS must be 




with IPA and acetone to clean away any residual PDMS before attempting a second 
bonding. 
